[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$foXZhq8SemTFSfdfrZ8IE6NiY41UNHwH_B9_5HMniCk4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":55,"rows":62},"Tehran University of Medical Sciences",[4],227,false,10,65,65214,6,97,[14,17,19,22,24,26,29,31],{"name":15,"count":16},"Type 2 Diabetes Mellitus",8,{"name":18,"count":16},"Pain",{"name":20,"count":21},"Obesity",5,{"name":23,"count":21},"Hepatitis C",{"name":25,"count":21},"Relapsing Remitting Multiple Sclerosis",{"name":27,"count":28},"Behcet's Syndrome",4,{"name":30,"count":28},"Cardiovascular Disease",{"name":32,"count":33},"Cutaneous Leishmaniasis",3,[35,40,45,50],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06536712","Effects of Exosome Adminstration in Preventing Early Leakage in Rectal Cancer Patients Undergoing Low Anterior Resection","2024-10","Mesenchymal Stem Cells Derived Exosomes",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT07325383","Safety and Efficacy of N-Acetylcysteine Mouthwash in Prevention of Mucositis in HSCT Patients","2025-03-08","N-Acetylcysteine 600mg\u002Ftab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT07305883","Comparison of Intranasal Ketorolac and Intranasal Ketamine in Digital Nerve Block Pain","2026-06-20","Intranasal Ketorolac Tromethamine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06555003","DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases","2027-10","Drug-Eluting Embolic Bead",[56,57,58,59,60,61],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[63,89,114,132,156,174,196,242,294,345,382,418,440,475,503,533,570,596,618,643,661,684,706,732,758,776,794,821,839,861,879,902,927,951,976,994,1012,1030,1054,1072,1093,1111,1137,1193,1227,1259,1295,1329,1351,1375,1398,1416,1440,1463,1489,1515,1536,1561,1586,1604,1629,1647,1671,1689,1715,1733,1755,1780,1806,1829,1852,1878,1901,1926,1944,1968,1994,2012,2036,2054,2076,2094,2116,2139,2157,2181,2199,2223,2241,2265,2283,2301,2327,2345,2371,2389,2407,2450,2489,2513,2536,2554,2577,2595,2618,2645,2671,2689,2715,2733,2758,2776,2798,2816,2838,2861,2879,2904,2922,2945,2968,2994,3012,3037,3055,3079,3104,3127,3145,3163,3185,3203,3225,3248,3277,3300,3318,3336,3354,3372,3390,3417,3442,3464,3482,3528,3554,3586,3623,3649,3674,3692,3718,3744,3762,3780,3804,3822,3846,3869],{"intervention":44,"totalTrials":64,"cells":65},1,{"EARLY_PHASE1":66,"PHASE1":69,"PHASE2":71,"PHASE3":73,"PHASE4":85,"NA":87},{"trials":67,"activeCount":68},[],0,{"trials":70,"activeCount":68},[],{"trials":72,"activeCount":68},[],{"trials":74,"activeCount":64,"soonestReadout":43},[75],{"nctId":41,"briefTitle":42,"status":76,"phases":77,"primaryCompletion":43,"completion":78,"start":79,"enrollment":80,"conditions":81,"interventions":84},"ACTIVE_NOT_RECRUITING",[59],"2026-02","2024-08-18",106,[82,83],"Oral Mucositis","Hematopoietic Stem Cell Transplantation (HSCT)",[44],{"trials":86,"activeCount":68},[],{"trials":88,"activeCount":68},[],{"intervention":54,"totalTrials":64,"cells":90},{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":110,"NA":112},{"trials":92,"activeCount":68},[],{"trials":94,"activeCount":68},[],{"trials":96,"activeCount":68},[],{"trials":98,"activeCount":64,"soonestReadout":53},[99],{"nctId":51,"briefTitle":52,"status":100,"phases":101,"primaryCompletion":53,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":108},"RECRUITING",[59],"2027-12","2025-01-20",116,[106,107],"Liver Neoplasm","Colorectal Cancer Metastatic",[54,109],"Chemotherapy drug",{"trials":111,"activeCount":68},[],{"trials":113,"activeCount":68},[],{"intervention":109,"totalTrials":64,"cells":115},{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":128,"NA":130},{"trials":117,"activeCount":68},[],{"trials":119,"activeCount":68},[],{"trials":121,"activeCount":68},[],{"trials":123,"activeCount":64,"soonestReadout":53},[124],{"nctId":51,"briefTitle":52,"status":100,"phases":125,"primaryCompletion":53,"completion":102,"start":103,"enrollment":104,"conditions":126,"interventions":127},[59],[106,107],[54,109],{"trials":129,"activeCount":68},[],{"trials":131,"activeCount":68},[],{"intervention":49,"totalTrials":64,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":152,"NA":154},{"trials":135,"activeCount":68},[],{"trials":137,"activeCount":68},[],{"trials":139,"activeCount":68},[],{"trials":141,"activeCount":64,"soonestReadout":48},[142],{"nctId":46,"briefTitle":47,"status":143,"phases":144,"primaryCompletion":48,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},"NOT_YET_RECRUITING",[59],"2026-08-01","2025-12-28",64,[18,149],"Digital Block",[49,151],"Intranasal ketamine",{"trials":153,"activeCount":68},[],{"trials":155,"activeCount":68},[],{"intervention":151,"totalTrials":64,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":170,"NA":172},{"trials":159,"activeCount":68},[],{"trials":161,"activeCount":68},[],{"trials":163,"activeCount":68},[],{"trials":165,"activeCount":64,"soonestReadout":48},[166],{"nctId":46,"briefTitle":47,"status":143,"phases":167,"primaryCompletion":48,"completion":145,"start":146,"enrollment":147,"conditions":168,"interventions":169},[59],[18,149],[49,151],{"trials":171,"activeCount":68},[],{"trials":173,"activeCount":68},[],{"intervention":39,"totalTrials":64,"cells":175},{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":188,"PHASE3":190,"PHASE4":192,"NA":194},{"trials":177,"activeCount":68},[],{"trials":179,"activeCount":64,"soonestReadout":38},[180],{"nctId":36,"briefTitle":37,"status":143,"phases":181,"primaryCompletion":38,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},[57],"2024-12","2024-08",20,[186],"Rectal Cancer",[39],{"trials":189,"activeCount":68},[],{"trials":191,"activeCount":68},[],{"trials":193,"activeCount":68},[],{"trials":195,"activeCount":68},[],{"intervention":197,"totalTrials":33,"cells":198},"Morphine",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":240},{"trials":200,"activeCount":68},[],{"trials":202,"activeCount":68},[],{"trials":204,"activeCount":68},[],{"trials":206,"activeCount":68},[],{"trials":208,"activeCount":68},[209,221,230],{"nctId":210,"briefTitle":211,"status":212,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT01298297","Efficacy of Buprenorphine for Treatment of Acute Pain","COMPLETED",[60],"2011-03","2010-02",80,[218],"Acute Pain",[220,197],"Buprenorphine",{"nctId":222,"briefTitle":223,"status":212,"phases":224,"primaryCompletion":225,"completion":225,"start":214,"enrollment":216,"conditions":226,"interventions":229},"NCT01546701","Buprenorphine in Acute Renal Colic Pain Management",[60],"2012-04",[227,228],"Acute Pain Management","Renal Colic",[220,197],{"nctId":231,"briefTitle":232,"status":212,"phases":233,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":239},"NCT00477061","Morphine Analgesia in Patients With Acute Appendicitis",[60],"2005-03","2004-01",71,[238],"Appendicitis",[197],{"trials":241,"activeCount":68},[],{"intervention":243,"totalTrials":33,"cells":244},"Midazolam",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":266,"NA":292},{"trials":246,"activeCount":68},[],{"trials":248,"activeCount":68},[],{"trials":250,"activeCount":68},[],{"trials":252,"activeCount":68},[253],{"nctId":254,"briefTitle":255,"status":256,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},"NCT01768377","Comparison of Intubation With Nerve Block and With Sedation in Awake Patients","UNKNOWN",[59],"2013-02","2012-11",70,[262],"Intubation Complication",[264,265,243],"Nerve block with Lidocain","Fentanyl",{"trials":267,"activeCount":68},[268,281],{"nctId":269,"briefTitle":270,"status":212,"phases":271,"primaryCompletion":272,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":278},"NCT02909465","Reducing Ketamine-Induced Agitation, by Midazolam or Haloperidol Premedication After Adult Procedural Sedation",[60],"2017-04","2017-07","2016-07",185,[277],"Ketamine Induced Agitation",[243,279,280],"Haloperidol","Ketamine",{"nctId":282,"briefTitle":283,"status":256,"phases":284,"primaryCompletion":285,"completion":258,"start":286,"enrollment":287,"conditions":288,"interventions":290},"NCT01749579","Comparison of Propofol-fentanyl and Midazolam-fentanyl for Conscious Sedation",[60],"2013-01","2012-05",60,[289],"Emergencies",[291,243,265],"Propofol",{"trials":293,"activeCount":68},[],{"intervention":295,"totalTrials":33,"cells":296},"Ribavirin",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":329,"NA":343},{"trials":298,"activeCount":68},[],{"trials":300,"activeCount":68},[],{"trials":302,"activeCount":68},[],{"trials":304,"activeCount":68},[305,318],{"nctId":306,"briefTitle":307,"status":212,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT02705534","Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1",[59],"2017-09","2017-10","2016-09",50,[23,314],"Cirrhosis",[316,317,295],"Sofosbuvir","Ledipasvir",{"nctId":319,"briefTitle":320,"status":212,"phases":321,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":327},"NCT02596880","Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics",[59],"2016-04","2016-06","2015-09",100,[23,314],[316,328,295],"Daclatasvir",{"trials":330,"activeCount":68},[331],{"nctId":332,"briefTitle":333,"status":212,"phases":334,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":340},"NCT00560690","The Effect of Adding Metformin to the Treatment of Hepatitis C",[60],"2010-09","2010-12","2007-12",140,[23],[341,342,295],"Metformin","pegylated interferon",{"trials":344,"activeCount":68},[],{"intervention":346,"totalTrials":347,"cells":348},"Vitamin A",2,{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":380},{"trials":350,"activeCount":68},[],{"trials":352,"activeCount":68},[],{"trials":354,"activeCount":68},[],{"trials":356,"activeCount":68},[],{"trials":358,"activeCount":68},[359,370],{"nctId":360,"briefTitle":361,"status":256,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},"NCT01414972","The Effect of Vitamin A on Atherosclerosis",[60],"2011-01","2011-11","2010-05",45,[368],"Atherosclerosis",[346],{"nctId":371,"briefTitle":372,"status":256,"phases":373,"primaryCompletion":374,"completion":375,"start":376,"enrollment":287,"conditions":377,"interventions":378},"NCT00963222","The Study of the Effects of Vitamin A on Immune System in Patients With Atherosclerosis",[60],"2011-09","2013-03","2009-09",[368],[379],"vitamin A",{"trials":381,"activeCount":68},[],{"intervention":383,"totalTrials":347,"cells":384},"sofosbuvir and daclatasvir",{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":405,"NA":416},{"trials":386,"activeCount":68},[],{"trials":388,"activeCount":68},[],{"trials":390,"activeCount":68},[],{"trials":392,"activeCount":68},[393],{"nctId":394,"briefTitle":395,"status":212,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":404},"NCT03369327","Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus",[59],"2018-09-01","2018-12-01","2017-01-01",232,[402,403],"Hepatitis C Virus Infection, Response to Therapy of","Human Immunodeficiency Virus",[383],{"trials":406,"activeCount":68},[407],{"nctId":408,"briefTitle":409,"status":212,"phases":410,"primaryCompletion":411,"completion":397,"start":412,"enrollment":413,"conditions":414,"interventions":415},"NCT03200184","Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients",[60],"2018-04-01","2016-09-01",1448,[23],[383],{"trials":417,"activeCount":68},[],{"intervention":220,"totalTrials":347,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":438},{"trials":421,"activeCount":68},[],{"trials":423,"activeCount":68},[],{"trials":425,"activeCount":68},[],{"trials":427,"activeCount":68},[],{"trials":429,"activeCount":68},[430,434],{"nctId":210,"briefTitle":211,"status":212,"phases":431,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":432,"interventions":433},[60],[218],[220,197],{"nctId":222,"briefTitle":223,"status":212,"phases":435,"primaryCompletion":225,"completion":225,"start":214,"enrollment":216,"conditions":436,"interventions":437},[60],[227,228],[220,197],{"trials":439,"activeCount":68},[],{"intervention":441,"totalTrials":347,"cells":442},"Pentoxifylline",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":459,"PHASE4":461,"NA":473},{"trials":444,"activeCount":68},[],{"trials":446,"activeCount":68},[],{"trials":448,"activeCount":68},[449],{"nctId":450,"briefTitle":451,"status":212,"phases":452,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":458},"NCT02283710","The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver Disease",[58],"2014-05","2013-05",120,[457],"Fatty Liver",[441],{"trials":460,"activeCount":68},[],{"trials":462,"activeCount":68},[463],{"nctId":464,"briefTitle":465,"status":212,"phases":466,"primaryCompletion":324,"completion":324,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT03006952","Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy",[60],"2015-04",59,[470],"Diabetic Nephropathies",[441,472],"Losartan",{"trials":474,"activeCount":68},[],{"intervention":472,"totalTrials":347,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":493,"PHASE4":495,"NA":501},{"trials":478,"activeCount":68},[],{"trials":480,"activeCount":68},[],{"trials":482,"activeCount":68},[483],{"nctId":484,"briefTitle":485,"status":212,"phases":486,"primaryCompletion":323,"completion":323,"start":487,"enrollment":488,"conditions":489,"interventions":491},"NCT02663141","Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema",[58],"2015-06",57,[490],"Diabetic Macular Edema",[472,492],"Intravitreal bevacizumab",{"trials":494,"activeCount":68},[],{"trials":496,"activeCount":68},[497],{"nctId":464,"briefTitle":465,"status":212,"phases":498,"primaryCompletion":324,"completion":324,"start":467,"enrollment":468,"conditions":499,"interventions":500},[60],[470],[441,472],{"trials":502,"activeCount":68},[],{"intervention":280,"totalTrials":347,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":513,"NA":531},{"trials":506,"activeCount":68},[],{"trials":508,"activeCount":68},[],{"trials":510,"activeCount":68},[],{"trials":512,"activeCount":68},[],{"trials":514,"activeCount":68},[515,519],{"nctId":269,"briefTitle":270,"status":212,"phases":516,"primaryCompletion":272,"completion":273,"start":274,"enrollment":275,"conditions":517,"interventions":518},[60],[277],[243,279,280],{"nctId":520,"briefTitle":521,"status":212,"phases":522,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":529},"NCT06139380","Intranasal Ketamine Effectiveness in Reducing Intramuscular Injection Pain Before Sedation Among Children",[60],"2024-04-28","2024-05-31","2023-12-02",84,[18,528],"Intranasal Ketamine",[280,530],"Sterile water",{"trials":532,"activeCount":68},[],{"intervention":534,"totalTrials":347,"cells":535},"Verapamil",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":568},{"trials":537,"activeCount":68},[],{"trials":539,"activeCount":68},[],{"trials":541,"activeCount":68},[],{"trials":543,"activeCount":68},[],{"trials":545,"activeCount":68},[546,556],{"nctId":547,"briefTitle":548,"status":212,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":555},"NCT01655316","Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control",[60],"2011-08","2010-10",90,[554],"Paroxysmal Supraventricular Tachycardia",[534],{"nctId":557,"briefTitle":558,"status":212,"phases":559,"primaryCompletion":560,"completion":560,"start":561,"enrollment":552,"conditions":562,"interventions":564},"NCT01655303","Rate Control in Atrial Fibrillation",[60],"2011-12","2011-02",[563],"Rapid Ventricular Response Atrial Fibrillation",[565,566,534,567],"Propranolol","Metoprolol","Diltiazem",{"trials":569,"activeCount":68},[],{"intervention":567,"totalTrials":347,"cells":571},{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":594},{"trials":573,"activeCount":68},[],{"trials":575,"activeCount":68},[],{"trials":577,"activeCount":68},[],{"trials":579,"activeCount":68},[],{"trials":581,"activeCount":68},[582,586],{"nctId":557,"briefTitle":558,"status":212,"phases":583,"primaryCompletion":560,"completion":560,"start":561,"enrollment":552,"conditions":584,"interventions":585},[60],[563],[565,566,534,567],{"nctId":587,"briefTitle":588,"status":212,"phases":589,"primaryCompletion":590,"completion":590,"start":591,"enrollment":64,"conditions":592,"interventions":593},"NCT00893100","Evaluation of Pain Reduction After Hemorrhoidectomy With Use of Diltiazim Ointment 2%",[60],"2008-12","2007-10",[18],[567],{"trials":595,"activeCount":68},[],{"intervention":265,"totalTrials":347,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":610,"NA":616},{"trials":599,"activeCount":68},[],{"trials":601,"activeCount":68},[],{"trials":603,"activeCount":68},[],{"trials":605,"activeCount":68},[606],{"nctId":254,"briefTitle":255,"status":256,"phases":607,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":608,"interventions":609},[59],[262],[264,265,243],{"trials":611,"activeCount":68},[612],{"nctId":282,"briefTitle":283,"status":256,"phases":613,"primaryCompletion":285,"completion":258,"start":286,"enrollment":287,"conditions":614,"interventions":615},[60],[289],[291,243,265],{"trials":617,"activeCount":68},[],{"intervention":619,"totalTrials":64,"cells":620},"insulin glargine",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":629,"NA":641},{"trials":622,"activeCount":68},[],{"trials":624,"activeCount":68},[],{"trials":626,"activeCount":68},[],{"trials":628,"activeCount":68},[],{"trials":630,"activeCount":68},[631],{"nctId":632,"briefTitle":633,"status":212,"phases":634,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":639},"NCT01832935","Cost Effectiveness of Glargine Insulin Versus NPH Insulin",[60],"2012-07","2011-07",200,[15],[619,640],"Insulin NPH",{"trials":642,"activeCount":68},[],{"intervention":640,"totalTrials":64,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":659},{"trials":646,"activeCount":68},[],{"trials":648,"activeCount":68},[],{"trials":650,"activeCount":68},[],{"trials":652,"activeCount":68},[],{"trials":654,"activeCount":68},[655],{"nctId":632,"briefTitle":633,"status":212,"phases":656,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":657,"interventions":658},[60],[15],[619,640],{"trials":660,"activeCount":68},[],{"intervention":662,"totalTrials":64,"cells":663},"methylorednisolone",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":672,"NA":682},{"trials":665,"activeCount":68},[],{"trials":667,"activeCount":68},[],{"trials":669,"activeCount":68},[],{"trials":671,"activeCount":68},[],{"trials":673,"activeCount":68},[674],{"nctId":675,"briefTitle":676,"status":256,"phases":677,"primaryCompletion":636,"completion":550,"start":215,"enrollment":678,"conditions":679,"interventions":681},"NCT01306955","The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease",[60],34,[680],"Behcet's Disease",[662],{"trials":683,"activeCount":68},[],{"intervention":685,"totalTrials":64,"cells":686},"Dietary Supplement: vitamin A",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":695,"NA":704},{"trials":688,"activeCount":68},[],{"trials":690,"activeCount":68},[],{"trials":692,"activeCount":68},[],{"trials":694,"activeCount":68},[],{"trials":696,"activeCount":68},[697],{"nctId":698,"briefTitle":699,"status":256,"phases":700,"primaryCompletion":258,"completion":701,"start":215,"enrollment":184,"conditions":702,"interventions":703},"NCT01705457","Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis",[60],"2013-08",[25],[685],{"trials":705,"activeCount":68},[],{"intervention":707,"totalTrials":64,"cells":708},"Sofosbuvir 400 mg and daclatasvir 60 mg",{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":715,"PHASE4":717,"NA":730},{"trials":710,"activeCount":68},[],{"trials":712,"activeCount":68},[],{"trials":714,"activeCount":68},[],{"trials":716,"activeCount":68},[],{"trials":718,"activeCount":68},[719],{"nctId":720,"briefTitle":721,"status":212,"phases":722,"primaryCompletion":397,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":729},"NCT03063879","Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir",[60],"2019-02-01","2017-04-01",95,[727,728],"Hepatitis C, Chronic","Chronic Renal Failure",[707],{"trials":731,"activeCount":68},[],{"intervention":733,"totalTrials":64,"cells":734},"Half-Dose Depot Triptorelin",{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":741,"PHASE4":743,"NA":756},{"trials":736,"activeCount":68},[],{"trials":738,"activeCount":68},[],{"trials":740,"activeCount":68},[],{"trials":742,"activeCount":68},[],{"trials":744,"activeCount":68},[745],{"nctId":746,"briefTitle":747,"status":212,"phases":748,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":754},"NCT00461916","Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin",[60],"2006-12","2005-05",182,[753],"Infertility",[733,755],"Reduced-Dose Daily Buserelin",{"trials":757,"activeCount":68},[],{"intervention":755,"totalTrials":64,"cells":759},{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":768,"NA":774},{"trials":761,"activeCount":68},[],{"trials":763,"activeCount":68},[],{"trials":765,"activeCount":68},[],{"trials":767,"activeCount":68},[],{"trials":769,"activeCount":68},[770],{"nctId":746,"briefTitle":747,"status":212,"phases":771,"completion":749,"start":750,"enrollment":751,"conditions":772,"interventions":773},[60],[753],[733,755],{"trials":775,"activeCount":68},[],{"intervention":279,"totalTrials":64,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":792},{"trials":779,"activeCount":68},[],{"trials":781,"activeCount":68},[],{"trials":783,"activeCount":68},[],{"trials":785,"activeCount":68},[],{"trials":787,"activeCount":68},[788],{"nctId":269,"briefTitle":270,"status":212,"phases":789,"primaryCompletion":272,"completion":273,"start":274,"enrollment":275,"conditions":790,"interventions":791},[60],[277],[243,279,280],{"trials":793,"activeCount":68},[],{"intervention":795,"totalTrials":64,"cells":796},"Mesalazine",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":805,"NA":819},{"trials":798,"activeCount":68},[],{"trials":800,"activeCount":68},[],{"trials":802,"activeCount":68},[],{"trials":804,"activeCount":68},[],{"trials":806,"activeCount":68},[807],{"nctId":808,"briefTitle":809,"status":810,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":68,"conditions":814,"interventions":817},"NCT02190526","Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome","WITHDRAWN",[60],"2015-12","2014-09",[815,816],"Diarrhea- Predominant Irritable Bowel Syndrome","Quality of Life",[795,818],"Amitriptyline",{"trials":820,"activeCount":68},[],{"intervention":818,"totalTrials":64,"cells":822},{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":829,"PHASE4":831,"NA":837},{"trials":824,"activeCount":68},[],{"trials":826,"activeCount":68},[],{"trials":828,"activeCount":68},[],{"trials":830,"activeCount":68},[],{"trials":832,"activeCount":68},[833],{"nctId":808,"briefTitle":809,"status":810,"phases":834,"primaryCompletion":812,"completion":812,"start":813,"enrollment":68,"conditions":835,"interventions":836},[60],[815,816],[795,818],{"trials":838,"activeCount":68},[],{"intervention":840,"totalTrials":64,"cells":841},"Sufentanyl",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":859},{"trials":843,"activeCount":68},[],{"trials":845,"activeCount":68},[],{"trials":847,"activeCount":68},[],{"trials":849,"activeCount":68},[],{"trials":851,"activeCount":68},[852],{"nctId":853,"briefTitle":854,"status":212,"phases":855,"primaryCompletion":258,"completion":258,"start":856,"enrollment":312,"conditions":857,"interventions":858},"NCT01516268","The Effect of Adding Sufentanyl to Bupivacaine in Transversus Abdominis Plane Block to Reduce the Narcotic Dosage and Pain After Cesarean Delivery",[60],"2012-01",[18],[840],{"trials":860,"activeCount":68},[],{"intervention":530,"totalTrials":64,"cells":862},{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":877},{"trials":864,"activeCount":68},[],{"trials":866,"activeCount":68},[],{"trials":868,"activeCount":68},[],{"trials":870,"activeCount":68},[],{"trials":872,"activeCount":68},[873],{"nctId":520,"briefTitle":521,"status":212,"phases":874,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":875,"interventions":876},[60],[18,528],[280,530],{"trials":878,"activeCount":68},[],{"intervention":880,"totalTrials":64,"cells":881},"Paracetamol",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":890,"NA":900},{"trials":883,"activeCount":68},[],{"trials":885,"activeCount":68},[],{"trials":887,"activeCount":68},[],{"trials":889,"activeCount":68},[],{"trials":891,"activeCount":68},[892],{"nctId":893,"briefTitle":894,"status":212,"phases":895,"primaryCompletion":896,"completion":897,"start":364,"enrollment":287,"conditions":898,"interventions":899},"NCT01465984","Efficacy of Intravenous (IV) Paracetamol for Treatment of Acute Pain",[60],"2012-09","2012-12",[218],[880],{"trials":901,"activeCount":68},[],{"intervention":903,"totalTrials":64,"cells":904},"Digital nerve block with bupivacaine",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":913,"NA":925},{"trials":906,"activeCount":68},[],{"trials":908,"activeCount":68},[],{"trials":910,"activeCount":68},[],{"trials":912,"activeCount":68},[],{"trials":914,"activeCount":68},[915],{"nctId":916,"briefTitle":917,"status":212,"phases":918,"primaryCompletion":310,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":924},"NCT02908412","Non-invasive Perioperative Hb Monitoring in Spinal Surgery",[60],"2018-01","2017-01-04",23,[923],"Blood Loss, Surgical",[903],{"trials":926,"activeCount":68},[],{"intervention":928,"totalTrials":64,"cells":929},"Vancomycin",{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":938,"NA":949},{"trials":931,"activeCount":68},[],{"trials":933,"activeCount":68},[],{"trials":935,"activeCount":68},[],{"trials":937,"activeCount":68},[],{"trials":939,"activeCount":68},[940],{"nctId":941,"briefTitle":942,"status":256,"phases":943,"primaryCompletion":944,"completion":944,"start":324,"enrollment":945,"conditions":946,"interventions":948},"NCT02605213","Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients",[60],"2016-02",30,[947],"Primary Sclerosing Cholangitis",[928],{"trials":950,"activeCount":68},[],{"intervention":952,"totalTrials":64,"cells":953},"aspirin",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":974},{"trials":955,"activeCount":68},[],{"trials":957,"activeCount":68},[],{"trials":959,"activeCount":68},[],{"trials":961,"activeCount":68},[],{"trials":963,"activeCount":68},[964],{"nctId":965,"briefTitle":966,"status":212,"phases":967,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":973},"NCT01867281","The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases",[60],"2014-06","2013-06",32,[972],"Asthma, Aspirin-Induced",[952],{"trials":975,"activeCount":68},[],{"intervention":565,"totalTrials":64,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":992},{"trials":979,"activeCount":68},[],{"trials":981,"activeCount":68},[],{"trials":983,"activeCount":68},[],{"trials":985,"activeCount":68},[],{"trials":987,"activeCount":68},[988],{"nctId":557,"briefTitle":558,"status":212,"phases":989,"primaryCompletion":560,"completion":560,"start":561,"enrollment":552,"conditions":990,"interventions":991},[60],[563],[565,566,534,567],{"trials":993,"activeCount":68},[],{"intervention":566,"totalTrials":64,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1010},{"trials":997,"activeCount":68},[],{"trials":999,"activeCount":68},[],{"trials":1001,"activeCount":68},[],{"trials":1003,"activeCount":68},[],{"trials":1005,"activeCount":68},[1006],{"nctId":557,"briefTitle":558,"status":212,"phases":1007,"primaryCompletion":560,"completion":560,"start":561,"enrollment":552,"conditions":1008,"interventions":1009},[60],[563],[565,566,534,567],{"trials":1011,"activeCount":68},[],{"intervention":291,"totalTrials":64,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1022,"NA":1028},{"trials":1015,"activeCount":68},[],{"trials":1017,"activeCount":68},[],{"trials":1019,"activeCount":68},[],{"trials":1021,"activeCount":68},[],{"trials":1023,"activeCount":68},[1024],{"nctId":282,"briefTitle":283,"status":256,"phases":1025,"primaryCompletion":285,"completion":258,"start":286,"enrollment":287,"conditions":1026,"interventions":1027},[60],[289],[291,243,265],{"trials":1029,"activeCount":68},[],{"intervention":1031,"totalTrials":64,"cells":1032},"BIAsp 30",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1052},{"trials":1034,"activeCount":68},[],{"trials":1036,"activeCount":68},[],{"trials":1038,"activeCount":68},[],{"trials":1040,"activeCount":68},[],{"trials":1042,"activeCount":68},[1043],{"nctId":1044,"briefTitle":1045,"status":212,"phases":1046,"primaryCompletion":550,"completion":635,"start":636,"enrollment":1047,"conditions":1048,"interventions":1050},"NCT01889095","Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients",[60],160,[1049],"Diabetes Type 2",[1031,1051],"NPH\u002FReg",{"trials":1053,"activeCount":68},[],{"intervention":1051,"totalTrials":64,"cells":1055},{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1062,"PHASE4":1064,"NA":1070},{"trials":1057,"activeCount":68},[],{"trials":1059,"activeCount":68},[],{"trials":1061,"activeCount":68},[],{"trials":1063,"activeCount":68},[],{"trials":1065,"activeCount":68},[1066],{"nctId":1044,"briefTitle":1045,"status":212,"phases":1067,"primaryCompletion":550,"completion":635,"start":636,"enrollment":1047,"conditions":1068,"interventions":1069},[60],[1049],[1031,1051],{"trials":1071,"activeCount":68},[],{"intervention":1073,"totalTrials":64,"cells":1074},"Drug: placebo",{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1083,"NA":1091},{"trials":1076,"activeCount":68},[],{"trials":1078,"activeCount":68},[],{"trials":1080,"activeCount":68},[],{"trials":1082,"activeCount":68},[],{"trials":1084,"activeCount":68},[1085],{"nctId":1086,"briefTitle":1087,"status":256,"phases":1088,"primaryCompletion":258,"completion":701,"start":215,"enrollment":325,"conditions":1089,"interventions":1090},"NCT01417273","Impact of Vitamin A on Multiple Sclerosis (MS)",[60],[25],[1073],{"trials":1092,"activeCount":68},[],{"intervention":342,"totalTrials":64,"cells":1094},{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1101,"PHASE4":1103,"NA":1109},{"trials":1096,"activeCount":68},[],{"trials":1098,"activeCount":68},[],{"trials":1100,"activeCount":68},[],{"trials":1102,"activeCount":68},[],{"trials":1104,"activeCount":68},[1105],{"nctId":332,"briefTitle":333,"status":212,"phases":1106,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":1107,"interventions":1108},[60],[23],[341,342,295],{"trials":1110,"activeCount":68},[],{"intervention":1112,"totalTrials":64,"cells":1113},"S(+)-ketamine",{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1135},{"trials":1115,"activeCount":68},[],{"trials":1117,"activeCount":68},[],{"trials":1119,"activeCount":68},[],{"trials":1121,"activeCount":68},[],{"trials":1123,"activeCount":68},[1124],{"nctId":1125,"briefTitle":1126,"status":256,"phases":1127,"primaryCompletion":1128,"completion":1129,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1134},"NCT00532662","Postoperative Analgesia by Epidural vs IV Ketamine Concurrent With Caudal Anesthesia in Pediatric Orthopedic Surgery",[60],"2009-06","2009-07","2007-11",40,[1133],"Analgesia",[1112],{"trials":1136,"activeCount":68},[],{"intervention":1138,"totalTrials":28,"cells":1139},"Polypill",{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1159,"PHASE4":1189,"NA":1191},{"trials":1141,"activeCount":68},[],{"trials":1143,"activeCount":68},[],{"trials":1145,"activeCount":68},[1146],{"nctId":1147,"briefTitle":1148,"status":212,"phases":1149,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":1153,"conditions":1154,"interventions":1158},"NCT00603590","Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease",[58],"2008-06","2008-07","2006-11",475,[30,1155,1156,1157],"Hypertension","Hyperlipidemia","Heart Disease",[1138],{"trials":1160,"activeCount":68},[1161,1171,1181],{"nctId":1162,"briefTitle":1163,"status":212,"phases":1164,"primaryCompletion":919,"completion":1165,"start":1166,"enrollment":1167,"conditions":1168,"interventions":1170},"NCT01245608","Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.",[59],"2018-09","2011-10",2400,[1169],"Cardiovascular Diseases",[1138],{"nctId":1172,"briefTitle":1173,"status":256,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1179},"NCT03459560","Prevention of Cardiovascular Disease With Polypill Among Pars Cohort Participants",[59],"2022-03-20","2015-12-20",4415,[1169],[1180],"PolyPill",{"nctId":1182,"briefTitle":1183,"status":212,"phases":1184,"primaryCompletion":1185,"completion":1185,"start":561,"enrollment":1186,"conditions":1187,"interventions":1188},"NCT01271985","Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill",[59],"2019-01",8410,[1169],[1180],{"trials":1190,"activeCount":68},[],{"trials":1192,"activeCount":68},[],{"intervention":1194,"totalTrials":347,"cells":1195},"SIMVASTATIN",{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1202,"PHASE4":1223,"NA":1225},{"trials":1197,"activeCount":68},[],{"trials":1199,"activeCount":68},[],{"trials":1201,"activeCount":68},[],{"trials":1203,"activeCount":68},[1204,1213],{"nctId":1205,"briefTitle":1206,"status":212,"phases":1207,"completion":1208,"start":1209,"enrollment":455,"conditions":1210,"interventions":1212},"NCT00575601","Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients",[59],"2009-04","2007-08",[1211],"Polycystic Ovary Syndrome",[1194],{"nctId":1214,"briefTitle":1215,"status":212,"phases":1216,"primaryCompletion":1217,"completion":1218,"start":1219,"enrollment":216,"conditions":1220,"interventions":1221},"NCT00668343","Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo",[59],"2008-03","2009-03","2005-04",[25],[1222],"simvastatin",{"trials":1224,"activeCount":68},[],{"trials":1226,"activeCount":68},[],{"intervention":1228,"totalTrials":347,"cells":1229},"Alum-ALM + BCG",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1236,"PHASE4":1255,"NA":1257},{"trials":1231,"activeCount":68},[],{"trials":1233,"activeCount":68},[],{"trials":1235,"activeCount":68},[],{"trials":1237,"activeCount":68},[1238,1248],{"nctId":1239,"briefTitle":1240,"status":212,"phases":1241,"primaryCompletion":1242,"completion":337,"start":1243,"enrollment":1244,"conditions":1245,"interventions":1247},"NCT00429715","Safety\u002FEfficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin",[58,59],"2007-05","2007-01",150,[1246],"Healthy",[1228,1228,1228],{"nctId":1249,"briefTitle":1250,"status":212,"phases":1251,"primaryCompletion":1252,"completion":337,"start":1243,"enrollment":325,"conditions":1253,"interventions":1254},"NCT00429780","Safety\u002FEfficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0)",[58,59],"2007-09",[1246],[1228],{"trials":1256,"activeCount":68},[],{"trials":1258,"activeCount":68},[],{"intervention":1260,"totalTrials":347,"cells":1261},"erythropoietin",{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1277,"PHASE4":1291,"NA":1293},{"trials":1263,"activeCount":68},[],{"trials":1265,"activeCount":68},[],{"trials":1267,"activeCount":68},[1268],{"nctId":1269,"briefTitle":1270,"status":256,"phases":1271,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":184,"conditions":1274,"interventions":1276},"NCT00622934","Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients",[58],"2008-05","2007-07",[1275],"Multiple Trauma",[1260],{"trials":1278,"activeCount":68},[1279],{"nctId":1280,"briefTitle":1281,"status":256,"phases":1282,"primaryCompletion":1283,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1289},"NCT02376881","Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)",[59],"2019-03-30","2020-03-30","2015-03",24,[1288],"Optic Nerve Diseases",[1290],"Erythropoietin",{"trials":1292,"activeCount":68},[],{"trials":1294,"activeCount":68},[],{"intervention":1296,"totalTrials":347,"cells":1297},"botulinum toxin A",{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1325,"NA":1327},{"trials":1299,"activeCount":68},[],{"trials":1301,"activeCount":68},[],{"trials":1303,"activeCount":68},[],{"trials":1305,"activeCount":68},[1306,1315],{"nctId":1307,"briefTitle":1308,"status":256,"phases":1309,"primaryCompletion":1310,"completion":1310,"start":591,"enrollment":1131,"conditions":1311,"interventions":1313},"NCT00638066","Botulinum Toxin Injection for Treatment of Vaginismus",[59],"2008-04",[1312],"Vaginismus",[1314,1296],"botulinum toxin",{"nctId":1316,"briefTitle":1317,"status":212,"phases":1318,"primaryCompletion":1217,"completion":1310,"start":1209,"enrollment":1319,"conditions":1320,"interventions":1322},"NCT00497913","Dysport® Injection in the Treatment of Chronic Lateral Epicondylitis",[59],52,[1321],"Tennis Elbow",[1323,1324],"NaCl 0.9%","Botulinum Toxin A",{"trials":1326,"activeCount":68},[],{"trials":1328,"activeCount":68},[],{"intervention":316,"totalTrials":347,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1337,"PHASE4":1347,"NA":1349},{"trials":1332,"activeCount":68},[],{"trials":1334,"activeCount":68},[],{"trials":1336,"activeCount":68},[],{"trials":1338,"activeCount":68},[1339,1343],{"nctId":306,"briefTitle":307,"status":212,"phases":1340,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":1341,"interventions":1342},[59],[23,314],[316,317,295],{"nctId":319,"briefTitle":320,"status":212,"phases":1344,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":1345,"interventions":1346},[59],[23,314],[316,328,295],{"trials":1348,"activeCount":68},[],{"trials":1350,"activeCount":68},[],{"intervention":1352,"totalTrials":64,"cells":1353},"Miltefose",{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1371,"NA":1373},{"trials":1355,"activeCount":68},[],{"trials":1357,"activeCount":68},[],{"trials":1359,"activeCount":68},[],{"trials":1361,"activeCount":68},[1362],{"nctId":1363,"briefTitle":1364,"status":212,"phases":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1370},"NCT00351520","Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica",[59],"2007-06","2006-05",148,[32],[1352],{"trials":1372,"activeCount":68},[],{"trials":1374,"activeCount":68},[],{"intervention":1376,"totalTrials":64,"cells":1377},"Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine",{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1384,"PHASE4":1394,"NA":1396},{"trials":1379,"activeCount":68},[],{"trials":1381,"activeCount":68},[],{"trials":1383,"activeCount":68},[],{"trials":1385,"activeCount":68},[1386],{"nctId":1387,"briefTitle":1388,"status":256,"phases":1389,"primaryCompletion":259,"completion":897,"start":376,"enrollment":8,"conditions":1390,"interventions":1392},"NCT01087398","Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis",[58,59],[1391],"Osteopetrosis",[1376,1393],"Cyclosporin, Methotrexate",{"trials":1395,"activeCount":68},[],{"trials":1397,"activeCount":68},[],{"intervention":1393,"totalTrials":64,"cells":1399},{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1412,"NA":1414},{"trials":1401,"activeCount":68},[],{"trials":1403,"activeCount":68},[],{"trials":1405,"activeCount":68},[],{"trials":1407,"activeCount":68},[1408],{"nctId":1387,"briefTitle":1388,"status":256,"phases":1409,"primaryCompletion":259,"completion":897,"start":376,"enrollment":8,"conditions":1410,"interventions":1411},[58,59],[1391],[1376,1393],{"trials":1413,"activeCount":68},[],{"trials":1415,"activeCount":68},[],{"intervention":1417,"totalTrials":64,"cells":1418},"cefazolin",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1425,"PHASE4":1436,"NA":1438},{"trials":1420,"activeCount":68},[],{"trials":1422,"activeCount":68},[],{"trials":1424,"activeCount":68},[],{"trials":1426,"activeCount":68},[1427],{"nctId":1428,"briefTitle":1429,"status":212,"phases":1430,"completion":1431,"start":1432,"enrollment":552,"conditions":1433,"interventions":1435},"NCT00467948","Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients",[59],"2006-03","2004-06",[1434],"Laryngeal Cancer",[1417],{"trials":1437,"activeCount":68},[],{"trials":1439,"activeCount":68},[],{"intervention":1441,"totalTrials":64,"cells":1442},"sildenafil",{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1459,"NA":1461},{"trials":1444,"activeCount":68},[],{"trials":1446,"activeCount":68},[],{"trials":1448,"activeCount":68},[],{"trials":1450,"activeCount":68},[1451],{"nctId":1452,"briefTitle":1453,"status":256,"phases":1454,"primaryCompletion":1455,"completion":856,"start":1150,"enrollment":260,"conditions":1456,"interventions":1458},"NCT01107782","Sildenafil and Uteroplacental Perfusion",[58,59],"2010-06",[1457],"Fetal Growth Retardation",[1441],{"trials":1460,"activeCount":68},[],{"trials":1462,"activeCount":68},[],{"intervention":1464,"totalTrials":64,"cells":1465},"Oral 25-Hydroxyvitamin D3",{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1472,"PHASE4":1485,"NA":1487},{"trials":1467,"activeCount":68},[],{"trials":1469,"activeCount":68},[],{"trials":1471,"activeCount":68},[],{"trials":1473,"activeCount":68},[1474],{"nctId":1475,"briefTitle":1476,"status":256,"phases":1477,"primaryCompletion":1478,"completion":1479,"start":1480,"enrollment":1481,"conditions":1482,"interventions":1484},"NCT04386850","Oral 25-hydroxyvitamin D3 and COVID-19",[58,59],"2020-11-15","2021-03-15","2020-04-14",1500,[1483],"COVID 19",[1464],{"trials":1486,"activeCount":68},[],{"trials":1488,"activeCount":68},[],{"intervention":1490,"totalTrials":64,"cells":1491},"Miglustat",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1511,"NA":1513},{"trials":1493,"activeCount":68},[],{"trials":1495,"activeCount":68},[],{"trials":1497,"activeCount":68},[],{"trials":1499,"activeCount":68},[1500],{"nctId":1501,"briefTitle":1502,"status":1503,"phases":1504,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":945,"conditions":1507,"interventions":1510},"NCT03822013","Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD)","TERMINATED",[59],"2025-09-10","2019-01-14",[1508,1509],"GM2 Gangliosidosis","Supportive Care",[1490],{"trials":1512,"activeCount":68},[],{"trials":1514,"activeCount":68},[],{"intervention":1516,"totalTrials":64,"cells":1517},"Meglumine antimoniate",{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1524,"PHASE4":1532,"NA":1534},{"trials":1519,"activeCount":68},[],{"trials":1521,"activeCount":68},[],{"trials":1523,"activeCount":68},[],{"trials":1525,"activeCount":68},[1526],{"nctId":1527,"briefTitle":1528,"status":212,"phases":1529,"primaryCompletion":591,"completion":337,"start":1242,"conditions":1530,"interventions":1531},"NCT04340128","Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)",[59],[32],[1516,1516],{"trials":1533,"activeCount":68},[],{"trials":1535,"activeCount":68},[],{"intervention":1537,"totalTrials":64,"cells":1538},"Oligopin",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1545,"PHASE4":1557,"NA":1559},{"trials":1540,"activeCount":68},[],{"trials":1542,"activeCount":68},[],{"trials":1544,"activeCount":68},[],{"trials":1546,"activeCount":68},[1547],{"nctId":1548,"briefTitle":1549,"status":212,"phases":1550,"primaryCompletion":398,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1556},"NCT03260803","Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women",[59],"2019-03-01","2018-02-01",43,[1555],"Osteopenia",[1537],{"trials":1558,"activeCount":68},[],{"trials":1560,"activeCount":68},[],{"intervention":1562,"totalTrials":64,"cells":1563},"Fluoxetine",{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1570,"PHASE4":1582,"NA":1584},{"trials":1565,"activeCount":68},[],{"trials":1567,"activeCount":68},[],{"trials":1569,"activeCount":68},[],{"trials":1571,"activeCount":68},[1572],{"nctId":1573,"briefTitle":1574,"status":212,"phases":1575,"primaryCompletion":550,"completion":550,"start":1576,"enrollment":1577,"conditions":1578,"interventions":1580},"NCT01269788","Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial",[58,59],"2010-08",144,[1579],"Non-erosive Reflux Disease",[1562,1581,1581,1562],"Omeprazole",{"trials":1583,"activeCount":68},[],{"trials":1585,"activeCount":68},[],{"intervention":1581,"totalTrials":64,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1594,"PHASE4":1600,"NA":1602},{"trials":1589,"activeCount":68},[],{"trials":1591,"activeCount":68},[],{"trials":1593,"activeCount":68},[],{"trials":1595,"activeCount":68},[1596],{"nctId":1573,"briefTitle":1574,"status":212,"phases":1597,"primaryCompletion":550,"completion":550,"start":1576,"enrollment":1577,"conditions":1598,"interventions":1599},[58,59],[1579],[1562,1581,1581,1562],{"trials":1601,"activeCount":68},[],{"trials":1603,"activeCount":68},[],{"intervention":1605,"totalTrials":64,"cells":1606},"Ciclesonide",{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1613,"PHASE4":1625,"NA":1627},{"trials":1608,"activeCount":68},[],{"trials":1610,"activeCount":68},[],{"trials":1612,"activeCount":68},[],{"trials":1614,"activeCount":68},[1615],{"nctId":1616,"briefTitle":1617,"status":256,"phases":1618,"primaryCompletion":944,"completion":1619,"start":1620,"enrollment":970,"conditions":1621,"interventions":1623},"NCT02665806","Ciclesonide vs Fluticasone Nasal Sprays in Nasal Poplyposis",[59],"2016-03","2016-01",[1622],"Chronic Rhinosinustis With Polyps",[1605,1624],"Fluticasone",{"trials":1626,"activeCount":68},[],{"trials":1628,"activeCount":68},[],{"intervention":1624,"totalTrials":64,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1643,"NA":1645},{"trials":1632,"activeCount":68},[],{"trials":1634,"activeCount":68},[],{"trials":1636,"activeCount":68},[],{"trials":1638,"activeCount":68},[1639],{"nctId":1616,"briefTitle":1617,"status":256,"phases":1640,"primaryCompletion":944,"completion":1619,"start":1620,"enrollment":970,"conditions":1641,"interventions":1642},[59],[1622],[1605,1624],{"trials":1644,"activeCount":68},[],{"trials":1646,"activeCount":68},[],{"intervention":1648,"totalTrials":64,"cells":1649},"Desmopressin intranasal spray",{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1667,"NA":1669},{"trials":1651,"activeCount":68},[],{"trials":1653,"activeCount":68},[],{"trials":1655,"activeCount":68},[],{"trials":1657,"activeCount":68},[1658],{"nctId":1659,"briefTitle":1660,"status":256,"phases":1661,"primaryCompletion":375,"completion":375,"start":1662,"enrollment":1663,"conditions":1664,"interventions":1665},"NCT01742689","Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic",[59],"2012-03",88,[228,18],[1648,1666],"Indomethacin suppository",{"trials":1668,"activeCount":68},[],{"trials":1670,"activeCount":68},[],{"intervention":1666,"totalTrials":64,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":68},[],{"trials":1676,"activeCount":68},[],{"trials":1678,"activeCount":68},[],{"trials":1680,"activeCount":68},[1681],{"nctId":1659,"briefTitle":1660,"status":256,"phases":1682,"primaryCompletion":375,"completion":375,"start":1662,"enrollment":1663,"conditions":1683,"interventions":1684},[59],[228,18],[1648,1666],{"trials":1686,"activeCount":68},[],{"trials":1688,"activeCount":68},[],{"intervention":1690,"totalTrials":64,"cells":1691},"N-acetylcysteine",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1698,"PHASE4":1711,"NA":1713},{"trials":1693,"activeCount":68},[],{"trials":1695,"activeCount":68},[],{"trials":1697,"activeCount":68},[],{"trials":1699,"activeCount":68},[1700],{"nctId":1701,"briefTitle":1702,"status":212,"phases":1703,"primaryCompletion":1704,"completion":1704,"start":1705,"enrollment":552,"conditions":1706,"interventions":1710},"NCT00808795","Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease",[59],"2006-10","2006-04",[1707,1708,1709],"Radiocontrast-Induced Nephropathy","Chronic Kidney Disease","Diabetes Mellitus",[1690],{"trials":1712,"activeCount":68},[],{"trials":1714,"activeCount":68},[],{"intervention":1314,"totalTrials":64,"cells":1716},{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1723,"PHASE4":1729,"NA":1731},{"trials":1718,"activeCount":68},[],{"trials":1720,"activeCount":68},[],{"trials":1722,"activeCount":68},[],{"trials":1724,"activeCount":68},[1725],{"nctId":1307,"briefTitle":1308,"status":256,"phases":1726,"primaryCompletion":1310,"completion":1310,"start":591,"enrollment":1131,"conditions":1727,"interventions":1728},[59],[1312],[1314,1296],{"trials":1730,"activeCount":68},[],{"trials":1732,"activeCount":68},[],{"intervention":1734,"totalTrials":64,"cells":1735},"Acyclovir",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1742,"PHASE4":1751,"NA":1753},{"trials":1737,"activeCount":68},[],{"trials":1739,"activeCount":68},[],{"trials":1741,"activeCount":68},[],{"trials":1743,"activeCount":68},[1744],{"nctId":1745,"briefTitle":1746,"status":256,"phases":1747,"primaryCompletion":897,"start":550,"enrollment":216,"conditions":1748,"interventions":1750},"NCT01729767","Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease",[58,59],[1749],"Meniere's Disease",[1734],{"trials":1752,"activeCount":68},[],{"trials":1754,"activeCount":68},[],{"intervention":1756,"totalTrials":64,"cells":1757},"Lidocaine-Prilocaine cream",{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1762,"PHASE3":1764,"PHASE4":1776,"NA":1778},{"trials":1759,"activeCount":68},[],{"trials":1761,"activeCount":68},[],{"trials":1763,"activeCount":68},[],{"trials":1765,"activeCount":68},[1766],{"nctId":1767,"briefTitle":1768,"status":212,"phases":1769,"primaryCompletion":1770,"completion":524,"start":1771,"enrollment":1772,"conditions":1773,"interventions":1774},"NCT04473820","Comparison of Lidocaine-Prilocaine Combination and Vapocoolant for IV Cannulation Pain in the ED",[59],"2024-04-29","2024-02-16",77,[18],[1775,1756],"Vapocoolant spray",{"trials":1777,"activeCount":68},[],{"trials":1779,"activeCount":68},[],{"intervention":1781,"totalTrials":64,"cells":1782},"Cyclosporine-A",{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1787,"PHASE3":1789,"PHASE4":1802,"NA":1804},{"trials":1784,"activeCount":68},[],{"trials":1786,"activeCount":68},[],{"trials":1788,"activeCount":68},[],{"trials":1790,"activeCount":68},[1791],{"nctId":1792,"briefTitle":1793,"status":212,"phases":1794,"primaryCompletion":1795,"completion":1796,"start":1797,"enrollment":1798,"conditions":1799,"interventions":1801},"NCT01170351","Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis",[59],"2013-12","2018-12","2005-12",55,[1800],"Autoimmune Hepatitis",[1781],{"trials":1803,"activeCount":68},[],{"trials":1805,"activeCount":68},[],{"intervention":1807,"totalTrials":64,"cells":1808},"Granulocyte Colony Stimulating Factor",{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1815,"PHASE4":1825,"NA":1827},{"trials":1810,"activeCount":68},[],{"trials":1812,"activeCount":68},[],{"trials":1814,"activeCount":68},[],{"trials":1816,"activeCount":68},[1817],{"nctId":1818,"briefTitle":1819,"status":212,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":259,"enrollment":1131,"conditions":1822,"interventions":1824},"NCT01825551","The Effect of GCSF in the Treatment of ALS Patients",[58,59],"2013-11",[1823],"Amyotrophic Lateral Sclerosis",[1807],{"trials":1826,"activeCount":68},[],{"trials":1828,"activeCount":68},[],{"intervention":1830,"totalTrials":64,"cells":1831},"Pioglitazone+Citalopram+Chlordiazepoxide",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1848,"NA":1850},{"trials":1833,"activeCount":68},[],{"trials":1835,"activeCount":68},[],{"trials":1837,"activeCount":68},[],{"trials":1839,"activeCount":68},[1840],{"nctId":1841,"briefTitle":1842,"status":212,"phases":1843,"primaryCompletion":1166,"completion":1166,"start":1844,"enrollment":312,"conditions":1845,"interventions":1847},"NCT01109030","Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder",[58,59],"2010-04",[1846],"Major Depressive Disorder",[1830],{"trials":1849,"activeCount":68},[],{"trials":1851,"activeCount":68},[],{"intervention":1853,"totalTrials":64,"cells":1854},"Zinc Sulfate",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1874,"NA":1876},{"trials":1856,"activeCount":68},[],{"trials":1858,"activeCount":68},[],{"trials":1860,"activeCount":68},[],{"trials":1862,"activeCount":68},[1863],{"nctId":1864,"briefTitle":1865,"status":212,"phases":1866,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":287,"conditions":1870,"interventions":1873},"NCT01015183","Prevention Chemotherapy Induced Mucositis by Zinc Sulfate",[58,59],"2010-11","2011-06","2009-11",[1871,1872],"Mucositis","Bone Marrow Transplantation",[1853],{"trials":1875,"activeCount":68},[],{"trials":1877,"activeCount":68},[],{"intervention":1879,"totalTrials":64,"cells":1880},"Pegaferon (pegylated interferon alpha 2a) + ribavirin",{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1887,"PHASE4":1897,"NA":1899},{"trials":1882,"activeCount":68},[],{"trials":1884,"activeCount":68},[],{"trials":1886,"activeCount":68},[],{"trials":1888,"activeCount":68},[1889],{"nctId":1890,"briefTitle":1891,"status":212,"phases":1892,"primaryCompletion":1893,"completion":215,"start":337,"enrollment":1894,"conditions":1895,"interventions":1896},"NCT01137383","Pegaferon and Ribavirin for Hepatitis C",[59],"2009-12",108,[23],[1879],{"trials":1898,"activeCount":68},[],{"trials":1900,"activeCount":68},[],{"intervention":1902,"totalTrials":64,"cells":1903},"Sitagliptin 100mg",{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1910,"PHASE4":1922,"NA":1924},{"trials":1905,"activeCount":68},[],{"trials":1907,"activeCount":68},[],{"trials":1909,"activeCount":68},[],{"trials":1911,"activeCount":68},[1912],{"nctId":1913,"briefTitle":1914,"status":212,"phases":1915,"primaryCompletion":724,"completion":724,"start":1916,"enrollment":1917,"conditions":1918,"interventions":1920},"NCT03125694","Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea",[59],"2015-02-01",250,[1919],"Uncontrolled Type 2 Diabetes Mellitus",[1902,1921],"Pioglitazone 30 mg",{"trials":1923,"activeCount":68},[],{"trials":1925,"activeCount":68},[],{"intervention":1921,"totalTrials":64,"cells":1927},{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1934,"PHASE4":1940,"NA":1942},{"trials":1929,"activeCount":68},[],{"trials":1931,"activeCount":68},[],{"trials":1933,"activeCount":68},[],{"trials":1935,"activeCount":68},[1936],{"nctId":1913,"briefTitle":1914,"status":212,"phases":1937,"primaryCompletion":724,"completion":724,"start":1916,"enrollment":1917,"conditions":1938,"interventions":1939},[59],[1919],[1902,1921],{"trials":1941,"activeCount":68},[],{"trials":1943,"activeCount":68},[],{"intervention":1945,"totalTrials":64,"cells":1946},"Stem cell Transplantation",{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1964,"NA":1966},{"trials":1948,"activeCount":68},[],{"trials":1950,"activeCount":68},[],{"trials":1952,"activeCount":68},[],{"trials":1954,"activeCount":68},[1955],{"nctId":1956,"briefTitle":1957,"status":256,"phases":1958,"primaryCompletion":897,"completion":285,"start":1869,"enrollment":8,"conditions":1959,"interventions":1963},"NCT01015742","Unrelated Double Umbilical Cord Blood Units Transplantation",[58,59],[1960,1961,1962],"Leukemia, Myeloid, Acute","Leukemia, Lymphoblastic, Acute","Leukemia, Myeloid, Chronic",[1945],{"trials":1965,"activeCount":68},[],{"trials":1967,"activeCount":68},[],{"intervention":1969,"totalTrials":64,"cells":1970},"Melatonin\u002Fexperimental",{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1977,"PHASE4":1990,"NA":1992},{"trials":1972,"activeCount":68},[],{"trials":1974,"activeCount":68},[],{"trials":1976,"activeCount":68},[],{"trials":1978,"activeCount":68},[1979],{"nctId":1980,"briefTitle":1981,"status":256,"phases":1982,"primaryCompletion":1983,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1989},"NCT03764020","Trial of Oral Melatonin in Elevated Blood Pressure",[59],"2019-11-01","2019-12-01","2019-06-01",320,[1988],"Elevated Blood Pressure",[1969],{"trials":1991,"activeCount":68},[],{"trials":1993,"activeCount":68},[],{"intervention":317,"totalTrials":64,"cells":1995},{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2008,"NA":2010},{"trials":1997,"activeCount":68},[],{"trials":1999,"activeCount":68},[],{"trials":2001,"activeCount":68},[],{"trials":2003,"activeCount":68},[2004],{"nctId":306,"briefTitle":307,"status":212,"phases":2005,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":2006,"interventions":2007},[59],[23,314],[316,317,295],{"trials":2009,"activeCount":68},[],{"trials":2011,"activeCount":68},[],{"intervention":2013,"totalTrials":64,"cells":2014},"Sodium Bicarbonate plus normal saline 0.9%",{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2021,"PHASE4":2032,"NA":2034},{"trials":2016,"activeCount":68},[],{"trials":2018,"activeCount":68},[],{"trials":2020,"activeCount":68},[],{"trials":2022,"activeCount":68},[2023],{"nctId":2024,"briefTitle":2025,"status":212,"phases":2026,"primaryCompletion":1150,"completion":1150,"start":1209,"enrollment":2027,"conditions":2028,"interventions":2030},"NCT00514150","Effect of Sodium Bicarbonate Solution in Decreasing the Incidence of Contrast Induced Nephropathy (CIN)",[59],265,[2029],"Contrast Induced Nephropathy",[2013,2031],"normal saline 0.9%",{"trials":2033,"activeCount":68},[],{"trials":2035,"activeCount":68},[],{"intervention":2031,"totalTrials":64,"cells":2037},{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2042,"PHASE3":2044,"PHASE4":2050,"NA":2052},{"trials":2039,"activeCount":68},[],{"trials":2041,"activeCount":68},[],{"trials":2043,"activeCount":68},[],{"trials":2045,"activeCount":68},[2046],{"nctId":2024,"briefTitle":2025,"status":212,"phases":2047,"primaryCompletion":1150,"completion":1150,"start":1209,"enrollment":2027,"conditions":2048,"interventions":2049},[59],[2029],[2013,2031],{"trials":2051,"activeCount":68},[],{"trials":2053,"activeCount":68},[],{"intervention":2055,"totalTrials":64,"cells":2056},"Zoledronic acid",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2063,"PHASE4":2072,"NA":2074},{"trials":2058,"activeCount":68},[],{"trials":2060,"activeCount":68},[],{"trials":2062,"activeCount":68},[],{"trials":2064,"activeCount":68},[2065],{"nctId":2066,"briefTitle":2067,"status":256,"phases":2068,"primaryCompletion":364,"completion":560,"start":1869,"enrollment":312,"conditions":2069,"interventions":2071},"NCT01016093","Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients",[58,59],[2070,1872],"Beta-Thalassemia",[2055],{"trials":2073,"activeCount":68},[],{"trials":2075,"activeCount":68},[],{"intervention":1323,"totalTrials":64,"cells":2077},{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2084,"PHASE4":2090,"NA":2092},{"trials":2079,"activeCount":68},[],{"trials":2081,"activeCount":68},[],{"trials":2083,"activeCount":68},[],{"trials":2085,"activeCount":68},[2086],{"nctId":1316,"briefTitle":1317,"status":212,"phases":2087,"primaryCompletion":1217,"completion":1310,"start":1209,"enrollment":1319,"conditions":2088,"interventions":2089},[59],[1321],[1323,1324],{"trials":2091,"activeCount":68},[],{"trials":2093,"activeCount":68},[],{"intervention":2095,"totalTrials":64,"cells":2096},"N-acetylcystein",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2112,"NA":2114},{"trials":2098,"activeCount":68},[],{"trials":2100,"activeCount":68},[],{"trials":2102,"activeCount":68},[],{"trials":2104,"activeCount":68},[2105],{"nctId":2106,"briefTitle":2107,"status":256,"phases":2108,"primaryCompletion":897,"completion":897,"start":363,"enrollment":325,"conditions":2109,"interventions":2111},"NCT01741207","Effect of N-acetylcystein in Myocardial Infarction",[59],[2110],"Acute Myocardial Infarction",[2095],{"trials":2113,"activeCount":68},[],{"trials":2115,"activeCount":68},[],{"intervention":2117,"totalTrials":64,"cells":2118},"Conditioning regimen",{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2123,"PHASE3":2125,"PHASE4":2135,"NA":2137},{"trials":2120,"activeCount":68},[],{"trials":2122,"activeCount":68},[],{"trials":2124,"activeCount":68},[],{"trials":2126,"activeCount":68},[2127],{"nctId":2128,"briefTitle":2129,"status":256,"phases":2130,"primaryCompletion":896,"completion":897,"start":376,"enrollment":8,"conditions":2131,"interventions":2133},"NCT01238328","Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis",[58,59],[2132],"Mucopolysaccharidosis",[2117,2134],"Graft-versus-host disease (GVHD) prophylaxis",{"trials":2136,"activeCount":68},[],{"trials":2138,"activeCount":68},[],{"intervention":2134,"totalTrials":64,"cells":2140},{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2145,"PHASE3":2147,"PHASE4":2153,"NA":2155},{"trials":2142,"activeCount":68},[],{"trials":2144,"activeCount":68},[],{"trials":2146,"activeCount":68},[],{"trials":2148,"activeCount":68},[2149],{"nctId":2128,"briefTitle":2129,"status":256,"phases":2150,"primaryCompletion":896,"completion":897,"start":376,"enrollment":8,"conditions":2151,"interventions":2152},[58,59],[2132],[2117,2134],{"trials":2154,"activeCount":68},[],{"trials":2156,"activeCount":68},[],{"intervention":2158,"totalTrials":64,"cells":2159},"standard care",{"EARLY_PHASE1":2160,"PHASE1":2162,"PHASE2":2164,"PHASE3":2166,"PHASE4":2177,"NA":2179},{"trials":2161,"activeCount":68},[],{"trials":2163,"activeCount":68},[],{"trials":2165,"activeCount":68},[],{"trials":2167,"activeCount":68},[2168],{"nctId":2169,"briefTitle":2170,"status":810,"phases":2171,"primaryCompletion":2172,"completion":968,"start":2173,"enrollment":68,"conditions":2174,"interventions":2176},"NCT01454869","The Effect of Heparin on Inhalation Injury",[59],"2012-06","2012-02",[2175],"Heparin",[2158,2175],{"trials":2178,"activeCount":68},[],{"trials":2180,"activeCount":68},[],{"intervention":2175,"totalTrials":64,"cells":2182},{"EARLY_PHASE1":2183,"PHASE1":2185,"PHASE2":2187,"PHASE3":2189,"PHASE4":2195,"NA":2197},{"trials":2184,"activeCount":68},[],{"trials":2186,"activeCount":68},[],{"trials":2188,"activeCount":68},[],{"trials":2190,"activeCount":68},[2191],{"nctId":2169,"briefTitle":2170,"status":810,"phases":2192,"primaryCompletion":2172,"completion":968,"start":2173,"enrollment":68,"conditions":2193,"interventions":2194},[59],[2175],[2158,2175],{"trials":2196,"activeCount":68},[],{"trials":2198,"activeCount":68},[],{"intervention":2200,"totalTrials":64,"cells":2201},"celecoxib",{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2208,"PHASE4":2219,"NA":2221},{"trials":2203,"activeCount":68},[],{"trials":2205,"activeCount":68},[],{"trials":2207,"activeCount":68},[],{"trials":2209,"activeCount":68},[2210],{"nctId":2211,"briefTitle":2212,"status":256,"phases":2213,"primaryCompletion":1209,"completion":2214,"start":1705,"enrollment":2215,"conditions":2216,"interventions":2218},"NCT00603759","COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma",[59],"2009-08",122,[2217],"Head and Neck Cancer",[2200],{"trials":2220,"activeCount":68},[],{"trials":2222,"activeCount":68},[],{"intervention":328,"totalTrials":64,"cells":2224},{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2229,"PHASE3":2231,"PHASE4":2237,"NA":2239},{"trials":2226,"activeCount":68},[],{"trials":2228,"activeCount":68},[],{"trials":2230,"activeCount":68},[],{"trials":2232,"activeCount":68},[2233],{"nctId":319,"briefTitle":320,"status":212,"phases":2234,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":2235,"interventions":2236},[59],[23,314],[316,328,295],{"trials":2238,"activeCount":68},[],{"trials":2240,"activeCount":68},[],{"intervention":2242,"totalTrials":64,"cells":2243},"Silymarin",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2250,"PHASE4":2261,"NA":2263},{"trials":2245,"activeCount":68},[],{"trials":2247,"activeCount":68},[],{"trials":2249,"activeCount":68},[],{"trials":2251,"activeCount":68},[2252],{"nctId":2253,"briefTitle":2254,"status":212,"phases":2255,"primaryCompletion":813,"completion":813,"start":701,"enrollment":945,"conditions":2256,"interventions":2259},"NCT01829178","Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma",[58,59],[2257,2258],"Upper GI Cancer","Cisplatin Adverse Reaction",[2242,2260],"chemotherapy",{"trials":2262,"activeCount":68},[],{"trials":2264,"activeCount":68},[],{"intervention":2260,"totalTrials":64,"cells":2266},{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2273,"PHASE4":2279,"NA":2281},{"trials":2268,"activeCount":68},[],{"trials":2270,"activeCount":68},[],{"trials":2272,"activeCount":68},[],{"trials":2274,"activeCount":68},[2275],{"nctId":2253,"briefTitle":2254,"status":212,"phases":2276,"primaryCompletion":813,"completion":813,"start":701,"enrollment":945,"conditions":2277,"interventions":2278},[58,59],[2257,2258],[2242,2260],{"trials":2280,"activeCount":68},[],{"trials":2282,"activeCount":68},[],{"intervention":264,"totalTrials":64,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2291,"PHASE4":2297,"NA":2299},{"trials":2286,"activeCount":68},[],{"trials":2288,"activeCount":68},[],{"trials":2290,"activeCount":68},[],{"trials":2292,"activeCount":68},[2293],{"nctId":254,"briefTitle":255,"status":256,"phases":2294,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":2295,"interventions":2296},[59],[262],[264,265,243],{"trials":2298,"activeCount":68},[],{"trials":2300,"activeCount":68},[],{"intervention":2302,"totalTrials":64,"cells":2303},"Long GnRH agonist + HRT",{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2310,"PHASE4":2323,"NA":2325},{"trials":2305,"activeCount":68},[],{"trials":2307,"activeCount":68},[],{"trials":2309,"activeCount":68},[],{"trials":2311,"activeCount":68},[2312],{"nctId":2313,"briefTitle":2314,"status":212,"phases":2315,"primaryCompletion":2316,"completion":2316,"start":2317,"enrollment":2318,"conditions":2319,"interventions":2321},"NCT05189873","GnRH Agonist Plus Hormone Replacement Therapy vs Hormone Replacement Therapy on IVF Outcomes",[59],"2022-01-03","2021-06-10",128,[1211,2320],"Infertility, Female",[2302,2322],"HRT",{"trials":2324,"activeCount":68},[],{"trials":2326,"activeCount":68},[],{"intervention":2322,"totalTrials":64,"cells":2328},{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2335,"PHASE4":2341,"NA":2343},{"trials":2330,"activeCount":68},[],{"trials":2332,"activeCount":68},[],{"trials":2334,"activeCount":68},[],{"trials":2336,"activeCount":68},[2337],{"nctId":2313,"briefTitle":2314,"status":212,"phases":2338,"primaryCompletion":2316,"completion":2316,"start":2317,"enrollment":2318,"conditions":2339,"interventions":2340},[59],[1211,2320],[2302,2322],{"trials":2342,"activeCount":68},[],{"trials":2344,"activeCount":68},[],{"intervention":2346,"totalTrials":64,"cells":2347},"betamethasone gel",{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2367,"NA":2369},{"trials":2349,"activeCount":68},[],{"trials":2351,"activeCount":68},[],{"trials":2353,"activeCount":68},[],{"trials":2355,"activeCount":68},[2356],{"nctId":2357,"briefTitle":2358,"status":212,"phases":2359,"primaryCompletion":375,"completion":375,"start":1662,"enrollment":2360,"conditions":2361,"interventions":2364},"NCT02114021","Effect of Betamethasone Gel and Lidocaine Jelly on Sore Throat, Cough and Hoarseness of",[59],99,[2362,2363],"Sore Throat","Cough",[2346,2365,2366],"lidocaine jelly","distilled water",{"trials":2368,"activeCount":68},[],{"trials":2370,"activeCount":68},[],{"intervention":2365,"totalTrials":64,"cells":2372},{"EARLY_PHASE1":2373,"PHASE1":2375,"PHASE2":2377,"PHASE3":2379,"PHASE4":2385,"NA":2387},{"trials":2374,"activeCount":68},[],{"trials":2376,"activeCount":68},[],{"trials":2378,"activeCount":68},[],{"trials":2380,"activeCount":68},[2381],{"nctId":2357,"briefTitle":2358,"status":212,"phases":2382,"primaryCompletion":375,"completion":375,"start":1662,"enrollment":2360,"conditions":2383,"interventions":2384},[59],[2362,2363],[2346,2365,2366],{"trials":2386,"activeCount":68},[],{"trials":2388,"activeCount":68},[],{"intervention":2366,"totalTrials":64,"cells":2390},{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2395,"PHASE3":2397,"PHASE4":2403,"NA":2405},{"trials":2392,"activeCount":68},[],{"trials":2394,"activeCount":68},[],{"trials":2396,"activeCount":68},[],{"trials":2398,"activeCount":68},[2399],{"nctId":2357,"briefTitle":2358,"status":212,"phases":2400,"primaryCompletion":375,"completion":375,"start":1662,"enrollment":2360,"conditions":2401,"interventions":2402},[59],[2362,2363],[2346,2365,2366],{"trials":2404,"activeCount":68},[],{"trials":2406,"activeCount":68},[],{"intervention":2408,"totalTrials":28,"cells":2409},"H.pylori eradication",{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2414,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2411,"activeCount":68},[],{"trials":2413,"activeCount":68},[],{"trials":2415,"activeCount":68},[2416,2425,2432,2438],{"nctId":2417,"briefTitle":2418,"status":212,"phases":2419,"primaryCompletion":2420,"completion":2420,"start":635,"enrollment":325,"conditions":2421,"interventions":2424},"NCT01876108","The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease",[58],"2013-07",[457,2422,2423],"Liver Dysfunction","Insulin Resistance",[2408],{"nctId":2426,"briefTitle":2427,"status":212,"phases":2428,"primaryCompletion":896,"completion":896,"start":225,"enrollment":1131,"conditions":2429,"interventions":2431},"NCT01654549","Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis",[58],[2430],"Non-alcoholic Fatty Liver Disease",[2408],{"nctId":2433,"briefTitle":2434,"status":212,"phases":2435,"primaryCompletion":969,"completion":969,"start":225,"enrollment":325,"conditions":2436,"interventions":2437},"NCT01759628","Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease",[58],[2430],[2408],{"nctId":2439,"briefTitle":2440,"status":212,"phases":2441,"primaryCompletion":258,"completion":375,"start":896,"enrollment":1131,"conditions":2442,"interventions":2443},"NCT01712711","Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease",[58],[2430],[2408],{"trials":2445,"activeCount":68},[],{"trials":2447,"activeCount":68},[],{"trials":2449,"activeCount":68},[],{"intervention":2451,"totalTrials":347,"cells":2452},"Methotrexate",{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2469,"PHASE3":2483,"PHASE4":2485,"NA":2487},{"trials":2454,"activeCount":68},[],{"trials":2456,"activeCount":68},[2457],{"nctId":2458,"briefTitle":2459,"status":212,"phases":2460,"completion":2461,"start":2462,"enrollment":8,"conditions":2463,"interventions":2464},"NCT00458250","Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H",[57],"2008-02","2006-09",[1960,1961],[2465,2466,2467,2468,2451],"Busulfan","Cyclophosphamide","CAMPATH-1H","Cyclosporin A",{"trials":2470,"activeCount":68},[2471],{"nctId":2472,"briefTitle":2473,"status":256,"phases":2474,"primaryCompletion":2475,"completion":2476,"start":2477,"enrollment":1244,"conditions":2478,"interventions":2480},"NCT05918718","Assessment of the Efficacy of Letrozole in the Treatment of Ectopic Pregnancy",[57,58],"2024-05-20","2024-12-20","2023-01-20",[2479],"Ectopic Pregnancy",[2481,2482],"Letrozole","methotrexate",{"trials":2484,"activeCount":68},[],{"trials":2486,"activeCount":68},[],{"trials":2488,"activeCount":68},[],{"intervention":2490,"totalTrials":64,"cells":2491},"Colchicine",{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2496,"PHASE3":2507,"PHASE4":2509,"NA":2511},{"trials":2493,"activeCount":68},[],{"trials":2495,"activeCount":68},[],{"trials":2497,"activeCount":68},[2498],{"nctId":2499,"briefTitle":2500,"status":212,"phases":2501,"primaryCompletion":2502,"completion":1367,"start":2503,"enrollment":2504,"conditions":2505,"interventions":2506},"NCT00700297","Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease",[58],"2005-10","2002-08",169,[27],[2490],{"trials":2508,"activeCount":68},[],{"trials":2510,"activeCount":68},[],{"trials":2512,"activeCount":68},[],{"intervention":2514,"totalTrials":64,"cells":2515},"Methylphenidate+placebo",{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2517,"activeCount":68},[],{"trials":2519,"activeCount":68},[],{"trials":2521,"activeCount":68},[2522],{"nctId":2523,"briefTitle":2524,"status":256,"phases":2525,"primaryCompletion":897,"completion":897,"start":1844,"enrollment":1131,"conditions":2526,"interventions":2528},"NCT01099072","Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder",[58],[2527],"Attention Deficit Hyperactivity Disorder",[2514,2529],"methylphenidate+carnitine",{"trials":2531,"activeCount":68},[],{"trials":2533,"activeCount":68},[],{"trials":2535,"activeCount":68},[],{"intervention":2529,"totalTrials":64,"cells":2537},{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2548,"PHASE4":2550,"NA":2552},{"trials":2539,"activeCount":68},[],{"trials":2541,"activeCount":68},[],{"trials":2543,"activeCount":68},[2544],{"nctId":2523,"briefTitle":2524,"status":256,"phases":2545,"primaryCompletion":897,"completion":897,"start":1844,"enrollment":1131,"conditions":2546,"interventions":2547},[58],[2527],[2514,2529],{"trials":2549,"activeCount":68},[],{"trials":2551,"activeCount":68},[],{"trials":2553,"activeCount":68},[],{"intervention":2555,"totalTrials":64,"cells":2556},"Rituximab",{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2558,"activeCount":68},[],{"trials":2560,"activeCount":68},[],{"trials":2562,"activeCount":68},[2563],{"nctId":2564,"briefTitle":2565,"status":212,"phases":2566,"primaryCompletion":2567,"completion":2567,"start":1705,"enrollment":184,"conditions":2568,"interventions":2569},"NCT00664599","Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease",[58],"2008-01",[27],[2555,2570],"Cytotoxic Combination",{"trials":2572,"activeCount":68},[],{"trials":2574,"activeCount":68},[],{"trials":2576,"activeCount":68},[],{"intervention":2570,"totalTrials":64,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2589,"PHASE4":2591,"NA":2593},{"trials":2580,"activeCount":68},[],{"trials":2582,"activeCount":68},[],{"trials":2584,"activeCount":68},[2585],{"nctId":2564,"briefTitle":2565,"status":212,"phases":2586,"primaryCompletion":2567,"completion":2567,"start":1705,"enrollment":184,"conditions":2587,"interventions":2588},[58],[27],[2555,2570],{"trials":2590,"activeCount":68},[],{"trials":2592,"activeCount":68},[],{"trials":2594,"activeCount":68},[],{"intervention":2596,"totalTrials":64,"cells":2597},"Marvelon",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2612,"PHASE4":2614,"NA":2616},{"trials":2599,"activeCount":68},[],{"trials":2601,"activeCount":68},[],{"trials":2603,"activeCount":68},[2604],{"nctId":2605,"briefTitle":2606,"status":256,"phases":2607,"primaryCompletion":335,"start":335,"enrollment":2608,"conditions":2609,"interventions":2611},"NCT01256619","Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women's Health",[58],61,[2610],"Women With PMS",[2596],{"trials":2613,"activeCount":68},[],{"trials":2615,"activeCount":68},[],{"trials":2617,"activeCount":68},[],{"intervention":2619,"totalTrials":64,"cells":2620},"mitochondria and MSC-derived exosomes",{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2639,"PHASE4":2641,"NA":2643},{"trials":2622,"activeCount":68},[],{"trials":2624,"activeCount":68},[],{"trials":2626,"activeCount":68},[2627],{"nctId":2628,"briefTitle":2629,"status":256,"phases":2630,"primaryCompletion":2631,"completion":2632,"start":2633,"enrollment":184,"conditions":2634,"interventions":2638},"NCT05669144","Co-transplantation of Mesenchymal Stem Cell Derived Exosomes and Autologous Mitochondria for Patients Candidate for CABG Surgery",[57,58],"2023-09-20","2024-09-20","2022-04-20",[2635,2636,2637],"Myocardial Infarction","Myocardial Ischemia","Myocardial Stunning",[2619],{"trials":2640,"activeCount":68},[],{"trials":2642,"activeCount":68},[],{"trials":2644,"activeCount":68},[],{"intervention":2646,"totalTrials":64,"cells":2647},"Recombinant human erythropoietin",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2649,"activeCount":68},[],{"trials":2651,"activeCount":68},[],{"trials":2653,"activeCount":68},[2654],{"nctId":2655,"briefTitle":2656,"status":212,"phases":2657,"primaryCompletion":322,"completion":2658,"start":2659,"enrollment":2660,"conditions":2661,"interventions":2663},"NCT01783847","Traumatic Optic Neuropathy Treatment Trial (TONTT)",[57,58],"2017-02","2015-02",117,[2662],"Traumatic Optic Neuropathy",[2646,2664],"Methyl prednisolone",{"trials":2666,"activeCount":68},[],{"trials":2668,"activeCount":68},[],{"trials":2670,"activeCount":68},[],{"intervention":2664,"totalTrials":64,"cells":2672},{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2683,"PHASE4":2685,"NA":2687},{"trials":2674,"activeCount":68},[],{"trials":2676,"activeCount":68},[],{"trials":2678,"activeCount":68},[2679],{"nctId":2655,"briefTitle":2656,"status":212,"phases":2680,"primaryCompletion":322,"completion":2658,"start":2659,"enrollment":2660,"conditions":2681,"interventions":2682},[57,58],[2662],[2646,2664],{"trials":2684,"activeCount":68},[],{"trials":2686,"activeCount":68},[],{"trials":2688,"activeCount":68},[],{"intervention":2690,"totalTrials":64,"cells":2691},"MNC",{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2693,"activeCount":68},[],{"trials":2695,"activeCount":68},[],{"trials":2697,"activeCount":68},[2698],{"nctId":2699,"briefTitle":2700,"status":256,"phases":2701,"primaryCompletion":2702,"completion":2703,"start":2704,"enrollment":1894,"conditions":2705,"interventions":2707},"NCT03795974","Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic and Mesenchymal Stem Cells in Cerebral Palsy",[58],"2019-10","2019-12","2017-07-23",[2706],"Cerebral Palsy, Spastic",[2690,2708],"MSC",{"trials":2710,"activeCount":68},[],{"trials":2712,"activeCount":68},[],{"trials":2714,"activeCount":68},[],{"intervention":2708,"totalTrials":64,"cells":2716},{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2727,"PHASE4":2729,"NA":2731},{"trials":2718,"activeCount":68},[],{"trials":2720,"activeCount":68},[],{"trials":2722,"activeCount":68},[2723],{"nctId":2699,"briefTitle":2700,"status":256,"phases":2724,"primaryCompletion":2702,"completion":2703,"start":2704,"enrollment":1894,"conditions":2725,"interventions":2726},[58],[2706],[2690,2708],{"trials":2728,"activeCount":68},[],{"trials":2730,"activeCount":68},[],{"trials":2732,"activeCount":68},[],{"intervention":2734,"totalTrials":64,"cells":2735},"Azathioprine",{"EARLY_PHASE1":2736,"PHASE1":2738,"PHASE2":2740,"PHASE3":2752,"PHASE4":2754,"NA":2756},{"trials":2737,"activeCount":68},[],{"trials":2739,"activeCount":68},[],{"trials":2741,"activeCount":68},[2742],{"nctId":2743,"briefTitle":2744,"status":212,"phases":2745,"primaryCompletion":2746,"completion":335,"start":2567,"enrollment":2747,"conditions":2748,"interventions":2750},"NCT00626678","Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone",[58],"2008-09",48,[2749],"Pemphigus Vulgaris",[2734,2751],"Prednisone",{"trials":2753,"activeCount":68},[],{"trials":2755,"activeCount":68},[],{"trials":2757,"activeCount":68},[],{"intervention":2751,"totalTrials":64,"cells":2759},{"EARLY_PHASE1":2760,"PHASE1":2762,"PHASE2":2764,"PHASE3":2770,"PHASE4":2772,"NA":2774},{"trials":2761,"activeCount":68},[],{"trials":2763,"activeCount":68},[],{"trials":2765,"activeCount":68},[2766],{"nctId":2743,"briefTitle":2744,"status":212,"phases":2767,"primaryCompletion":2746,"completion":335,"start":2567,"enrollment":2747,"conditions":2768,"interventions":2769},[58],[2749],[2734,2751],{"trials":2771,"activeCount":68},[],{"trials":2773,"activeCount":68},[],{"trials":2775,"activeCount":68},[],{"intervention":2777,"totalTrials":64,"cells":2778},"Amantadine",{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2792,"PHASE4":2794,"NA":2796},{"trials":2780,"activeCount":68},[],{"trials":2782,"activeCount":68},[],{"trials":2784,"activeCount":68},[2785],{"nctId":2786,"briefTitle":2787,"status":256,"phases":2788,"primaryCompletion":1844,"completion":1455,"start":1844,"enrollment":1131,"conditions":2789,"interventions":2790},"NCT01099059","Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)",[58],[2527],[2777,2791],"ritalin",{"trials":2793,"activeCount":68},[],{"trials":2795,"activeCount":68},[],{"trials":2797,"activeCount":68},[],{"intervention":2791,"totalTrials":64,"cells":2799},{"EARLY_PHASE1":2800,"PHASE1":2802,"PHASE2":2804,"PHASE3":2810,"PHASE4":2812,"NA":2814},{"trials":2801,"activeCount":68},[],{"trials":2803,"activeCount":68},[],{"trials":2805,"activeCount":68},[2806],{"nctId":2786,"briefTitle":2787,"status":256,"phases":2807,"primaryCompletion":1844,"completion":1455,"start":1844,"enrollment":1131,"conditions":2808,"interventions":2809},[58],[2527],[2777,2791],{"trials":2811,"activeCount":68},[],{"trials":2813,"activeCount":68},[],{"trials":2815,"activeCount":68},[],{"intervention":2817,"totalTrials":64,"cells":2818},"131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation",{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2832,"PHASE4":2834,"NA":2836},{"trials":2820,"activeCount":68},[],{"trials":2822,"activeCount":68},[],{"trials":2824,"activeCount":68},[2825],{"nctId":2826,"briefTitle":2827,"status":256,"phases":2828,"primaryCompletion":635,"start":2746,"enrollment":8,"conditions":2829,"interventions":2831},"NCT00798148","131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma",[57,58],[2830],"Neuroblastoma",[2817],{"trials":2833,"activeCount":68},[],{"trials":2835,"activeCount":68},[],{"trials":2837,"activeCount":68},[],{"intervention":2839,"totalTrials":64,"cells":2840},"Tranexamic acid",{"EARLY_PHASE1":2841,"PHASE1":2843,"PHASE2":2845,"PHASE3":2855,"PHASE4":2857,"NA":2859},{"trials":2842,"activeCount":68},[],{"trials":2844,"activeCount":68},[],{"trials":2846,"activeCount":68},[2847],{"nctId":2848,"briefTitle":2849,"status":212,"phases":2850,"primaryCompletion":1576,"completion":335,"start":376,"enrollment":325,"conditions":2851,"interventions":2853},"NCT01085006","The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery",[57,58],[2852],"Hemorrhage",[2839,2854],"Normal saline",{"trials":2856,"activeCount":68},[],{"trials":2858,"activeCount":68},[],{"trials":2860,"activeCount":68},[],{"intervention":2854,"totalTrials":64,"cells":2862},{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2867,"PHASE3":2873,"PHASE4":2875,"NA":2877},{"trials":2864,"activeCount":68},[],{"trials":2866,"activeCount":68},[],{"trials":2868,"activeCount":68},[2869],{"nctId":2848,"briefTitle":2849,"status":212,"phases":2870,"primaryCompletion":1576,"completion":335,"start":376,"enrollment":325,"conditions":2871,"interventions":2872},[57,58],[2852],[2839,2854],{"trials":2874,"activeCount":68},[],{"trials":2876,"activeCount":68},[],{"trials":2878,"activeCount":68},[],{"intervention":2880,"totalTrials":64,"cells":2881},"Atorvastatin",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2886,"PHASE3":2898,"PHASE4":2900,"NA":2902},{"trials":2883,"activeCount":68},[],{"trials":2885,"activeCount":68},[],{"trials":2887,"activeCount":68},[2888],{"nctId":2889,"briefTitle":2890,"status":256,"phases":2891,"primaryCompletion":2702,"completion":2703,"start":2892,"enrollment":2893,"conditions":2894,"interventions":2896},"NCT01617772","Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis",[58],"2016-01-01",440,[2895],"Non-alcoholic Steatohepatitis",[2880,2897],"L-Carnitine",{"trials":2899,"activeCount":68},[],{"trials":2901,"activeCount":68},[],{"trials":2903,"activeCount":68},[],{"intervention":2897,"totalTrials":64,"cells":2905},{"EARLY_PHASE1":2906,"PHASE1":2908,"PHASE2":2910,"PHASE3":2916,"PHASE4":2918,"NA":2920},{"trials":2907,"activeCount":68},[],{"trials":2909,"activeCount":68},[],{"trials":2911,"activeCount":68},[2912],{"nctId":2889,"briefTitle":2890,"status":256,"phases":2913,"primaryCompletion":2702,"completion":2703,"start":2892,"enrollment":2893,"conditions":2914,"interventions":2915},[58],[2895],[2880,2897],{"trials":2917,"activeCount":68},[],{"trials":2919,"activeCount":68},[],{"trials":2921,"activeCount":68},[],{"intervention":2923,"totalTrials":64,"cells":2924},"riboflavin 0.1% combined with dextran 20 %",{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2939,"PHASE4":2941,"NA":2943},{"trials":2926,"activeCount":68},[],{"trials":2928,"activeCount":68},[],{"trials":2930,"activeCount":68},[2931],{"nctId":2932,"briefTitle":2933,"status":256,"phases":2934,"primaryCompletion":812,"completion":944,"start":2935,"enrollment":1131,"conditions":2936,"interventions":2938},"NCT02507362","Adapted Fluence Settings for Corneal Collagen Cross-linking in Mild to Moderate Progressive Keratoconus",[57,58],"2014-08",[2937],"Keratoconus",[2923],{"trials":2940,"activeCount":68},[],{"trials":2942,"activeCount":68},[],{"trials":2944,"activeCount":68},[],{"intervention":2946,"totalTrials":64,"cells":2947},"vitamin E +Selenium",{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2962,"PHASE4":2964,"NA":2966},{"trials":2949,"activeCount":68},[],{"trials":2951,"activeCount":68},[],{"trials":2953,"activeCount":68},[2954],{"nctId":2955,"briefTitle":2956,"status":256,"phases":2957,"primaryCompletion":2958,"start":1868,"enrollment":287,"conditions":2959,"interventions":2961},"NCT01554345","Effect of Vitamin E+Selenium on Kidney Function in Controlled Hypotension",[58],"2012-08",[2960],"Acute Kidney Injury",[2946],{"trials":2963,"activeCount":68},[],{"trials":2965,"activeCount":68},[],{"trials":2967,"activeCount":68},[],{"intervention":2969,"totalTrials":64,"cells":2970},"Pasocovac vaccine",{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2975,"PHASE3":2988,"PHASE4":2990,"NA":2992},{"trials":2972,"activeCount":68},[],{"trials":2974,"activeCount":68},[],{"trials":2976,"activeCount":68},[2977],{"nctId":2978,"briefTitle":2979,"status":256,"phases":2980,"primaryCompletion":2981,"completion":2982,"start":2983,"enrollment":325,"conditions":2984,"interventions":2987},"NCT05185817","Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients",[58],"2022-07-01","2023-07-01","2021-11-01",[83,2985,2986],"COVID-19 Vaccines","Immune System Tolerance",[2969],{"trials":2989,"activeCount":68},[],{"trials":2991,"activeCount":68},[],{"trials":2993,"activeCount":68},[],{"intervention":2481,"totalTrials":64,"cells":2995},{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3006,"PHASE4":3008,"NA":3010},{"trials":2997,"activeCount":68},[],{"trials":2999,"activeCount":68},[],{"trials":3001,"activeCount":68},[3002],{"nctId":2472,"briefTitle":2473,"status":256,"phases":3003,"primaryCompletion":2475,"completion":2476,"start":2477,"enrollment":1244,"conditions":3004,"interventions":3005},[57,58],[2479],[2481,2482],{"trials":3007,"activeCount":68},[],{"trials":3009,"activeCount":68},[],{"trials":3011,"activeCount":68},[],{"intervention":3013,"totalTrials":64,"cells":3014},"Oral selenium",{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3031,"PHASE4":3033,"NA":3035},{"trials":3016,"activeCount":68},[],{"trials":3018,"activeCount":68},[],{"trials":3020,"activeCount":68},[3021],{"nctId":3022,"briefTitle":3023,"status":256,"phases":3024,"primaryCompletion":3025,"completion":897,"start":1868,"enrollment":3026,"conditions":3027,"interventions":3029},"NCT01432873","Oral Selenium Therapy for the Prevention of Mucositis",[57,58],"2012-10",76,[1871,3028],"Hematopoietic Stem Cell Transplantation",[3013,3030],"Oral placebo",{"trials":3032,"activeCount":68},[],{"trials":3034,"activeCount":68},[],{"trials":3036,"activeCount":68},[],{"intervention":3030,"totalTrials":64,"cells":3038},{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3049,"PHASE4":3051,"NA":3053},{"trials":3040,"activeCount":68},[],{"trials":3042,"activeCount":68},[],{"trials":3044,"activeCount":68},[3045],{"nctId":3022,"briefTitle":3023,"status":256,"phases":3046,"primaryCompletion":3025,"completion":897,"start":1868,"enrollment":3026,"conditions":3047,"interventions":3048},[57,58],[1871,3028],[3013,3030],{"trials":3050,"activeCount":68},[],{"trials":3052,"activeCount":68},[],{"trials":3054,"activeCount":68},[],{"intervention":3056,"totalTrials":64,"cells":3057},"spironolacone 25 mg tablets added to losartan",{"EARLY_PHASE1":3058,"PHASE1":3060,"PHASE2":3062,"PHASE3":3073,"PHASE4":3075,"NA":3077},{"trials":3059,"activeCount":68},[],{"trials":3061,"activeCount":68},[],{"trials":3063,"activeCount":68},[3064],{"nctId":3065,"briefTitle":3066,"status":212,"phases":3067,"primaryCompletion":1662,"completion":635,"start":365,"enrollment":3068,"conditions":3069,"interventions":3072},"NCT01667614","Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure",[58],136,[15,3070,3071],"Diabetic Nephropathy","Essential Hypertension",[3056],{"trials":3074,"activeCount":68},[],{"trials":3076,"activeCount":68},[],{"trials":3078,"activeCount":68},[],{"intervention":3080,"totalTrials":64,"cells":3081},"Phenytoin",{"EARLY_PHASE1":3082,"PHASE1":3084,"PHASE2":3086,"PHASE3":3098,"PHASE4":3100,"NA":3102},{"trials":3083,"activeCount":68},[],{"trials":3085,"activeCount":68},[],{"trials":3087,"activeCount":68},[3088],{"nctId":3089,"briefTitle":3090,"status":212,"phases":3091,"primaryCompletion":3092,"completion":3093,"start":3094,"enrollment":236,"conditions":3095,"interventions":3097},"NCT02939937","Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis",[58],"2018-11-11","2019-01-02","2017-03-09",[3096],"Optic Neuritis",[3080],{"trials":3099,"activeCount":68},[],{"trials":3101,"activeCount":68},[],{"trials":3103,"activeCount":68},[],{"intervention":3105,"totalTrials":64,"cells":3106},"Azithromycin",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3108,"activeCount":68},[],{"trials":3110,"activeCount":68},[],{"trials":3112,"activeCount":68},[3113],{"nctId":3114,"briefTitle":3115,"status":212,"phases":3116,"primaryCompletion":2420,"completion":2420,"start":285,"enrollment":325,"conditions":3117,"interventions":3119},"NCT01783860","Oral Azithromycin Versus Doxycycline in Posterior Blepharitis",[58],[3118],"Posterior Blepharitis",[3105,3120],"Doxycycline",{"trials":3122,"activeCount":68},[],{"trials":3124,"activeCount":68},[],{"trials":3126,"activeCount":68},[],{"intervention":3120,"totalTrials":64,"cells":3128},{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3133,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3130,"activeCount":68},[],{"trials":3132,"activeCount":68},[],{"trials":3134,"activeCount":68},[3135],{"nctId":3114,"briefTitle":3115,"status":212,"phases":3136,"primaryCompletion":2420,"completion":2420,"start":285,"enrollment":325,"conditions":3137,"interventions":3138},[58],[3118],[3105,3120],{"trials":3140,"activeCount":68},[],{"trials":3142,"activeCount":68},[],{"trials":3144,"activeCount":68},[],{"intervention":492,"totalTrials":64,"cells":3146},{"EARLY_PHASE1":3147,"PHASE1":3149,"PHASE2":3151,"PHASE3":3157,"PHASE4":3159,"NA":3161},{"trials":3148,"activeCount":68},[],{"trials":3150,"activeCount":68},[],{"trials":3152,"activeCount":68},[3153],{"nctId":484,"briefTitle":485,"status":212,"phases":3154,"primaryCompletion":323,"completion":323,"start":487,"enrollment":488,"conditions":3155,"interventions":3156},[58],[490],[472,492],{"trials":3158,"activeCount":68},[],{"trials":3160,"activeCount":68},[],{"trials":3162,"activeCount":68},[],{"intervention":3164,"totalTrials":64,"cells":3165},"Cytosar",{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3170,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3167,"activeCount":68},[],{"trials":3169,"activeCount":68},[],{"trials":3171,"activeCount":68},[3172],{"nctId":3173,"briefTitle":3174,"status":212,"phases":3175,"primaryCompletion":2461,"completion":2461,"start":591,"enrollment":8,"conditions":3176,"interventions":3177},"NCT00850304","Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide",[58],[1960],[3164,3178],"Arsenic trioxide",{"trials":3180,"activeCount":68},[],{"trials":3182,"activeCount":68},[],{"trials":3184,"activeCount":68},[],{"intervention":3178,"totalTrials":64,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3188,"activeCount":68},[],{"trials":3190,"activeCount":68},[],{"trials":3192,"activeCount":68},[3193],{"nctId":3173,"briefTitle":3174,"status":212,"phases":3194,"primaryCompletion":2461,"completion":2461,"start":591,"enrollment":8,"conditions":3195,"interventions":3196},[58],[1960],[3164,3178],{"trials":3198,"activeCount":68},[],{"trials":3200,"activeCount":68},[],{"trials":3202,"activeCount":68},[],{"intervention":3204,"totalTrials":64,"cells":3205},"Sodium Bicarbonate",{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3210,"PHASE3":3219,"PHASE4":3221,"NA":3223},{"trials":3207,"activeCount":68},[],{"trials":3209,"activeCount":68},[],{"trials":3211,"activeCount":68},[3212],{"nctId":3213,"briefTitle":3214,"status":212,"phases":3215,"primaryCompletion":1151,"completion":1151,"start":1209,"enrollment":3216,"conditions":3217,"interventions":3218},"NCT00513825","Preventing Contrast Nephropathy With Sodium Bicarbonate in Patients With Pulmonary Edema,Heart Failure,Uncontrolled HTN",[58],72,[2029],[3204],{"trials":3220,"activeCount":68},[],{"trials":3222,"activeCount":68},[],{"trials":3224,"activeCount":68},[],{"intervention":3226,"totalTrials":64,"cells":3227},"Adipose derived mesenchymal stem cell",{"EARLY_PHASE1":3228,"PHASE1":3230,"PHASE2":3232,"PHASE3":3242,"PHASE4":3244,"NA":3246},{"trials":3229,"activeCount":68},[],{"trials":3231,"activeCount":68},[],{"trials":3233,"activeCount":68},[3234],{"nctId":3235,"briefTitle":3236,"status":256,"phases":3237,"primaryCompletion":3238,"completion":273,"start":487,"enrollment":8,"conditions":3239,"interventions":3241},"NCT02855112","Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients",[57,58],"2016-12",[3240],"Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]",[3226],{"trials":3243,"activeCount":68},[],{"trials":3245,"activeCount":68},[],{"trials":3247,"activeCount":68},[],{"intervention":3249,"totalTrials":347,"cells":3250},"Autologous Stem Cell Transplantation",{"EARLY_PHASE1":3251,"PHASE1":3253,"PHASE2":3269,"PHASE3":3271,"PHASE4":3273,"NA":3275},{"trials":3252,"activeCount":68},[],{"trials":3254,"activeCount":68},[3255,3262],{"nctId":3256,"briefTitle":3257,"status":256,"phases":3258,"primaryCompletion":1867,"completion":1867,"start":337,"enrollment":21,"conditions":3259,"interventions":3261},"NCT00550524","Stem Cell Transplantation for the Treatment of Knee Osteoarthritis",[57],[3260],"Knee Osteoarthritis",[3249],{"nctId":3263,"briefTitle":3264,"status":1503,"phases":3265,"primaryCompletion":635,"completion":2420,"start":337,"enrollment":21,"conditions":3266,"interventions":3268},"NCT00550498","Stem Cell Transplantation in Ocular Lesions of Behcet's Disease",[57],[3267,27],"Retinitis",[3249],{"trials":3270,"activeCount":68},[],{"trials":3272,"activeCount":68},[],{"trials":3274,"activeCount":68},[],{"trials":3276,"activeCount":68},[],{"intervention":3278,"totalTrials":64,"cells":3279},"Bcr-abl multipeptide vaccine",{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3292,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3281,"activeCount":68},[],{"trials":3283,"activeCount":68},[3284],{"nctId":3285,"briefTitle":3286,"status":212,"phases":3287,"primaryCompletion":336,"completion":364,"start":2461,"enrollment":3288,"conditions":3289,"interventions":3290},"NCT00455221","Safety Assessment of a Multipeptide-gene Vaccine in CML",[57],12,[1962],[3278,3291],"Cytokine gene adjuvant",{"trials":3293,"activeCount":68},[],{"trials":3295,"activeCount":68},[],{"trials":3297,"activeCount":68},[],{"trials":3299,"activeCount":68},[],{"intervention":3291,"totalTrials":64,"cells":3301},{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3310,"PHASE3":3312,"PHASE4":3314,"NA":3316},{"trials":3303,"activeCount":68},[],{"trials":3305,"activeCount":68},[3306],{"nctId":3285,"briefTitle":3286,"status":212,"phases":3307,"primaryCompletion":336,"completion":364,"start":2461,"enrollment":3288,"conditions":3308,"interventions":3309},[57],[1962],[3278,3291],{"trials":3311,"activeCount":68},[],{"trials":3313,"activeCount":68},[],{"trials":3315,"activeCount":68},[],{"trials":3317,"activeCount":68},[],{"intervention":2465,"totalTrials":64,"cells":3319},{"EARLY_PHASE1":3320,"PHASE1":3322,"PHASE2":3328,"PHASE3":3330,"PHASE4":3332,"NA":3334},{"trials":3321,"activeCount":68},[],{"trials":3323,"activeCount":68},[3324],{"nctId":2458,"briefTitle":2459,"status":212,"phases":3325,"completion":2461,"start":2462,"enrollment":8,"conditions":3326,"interventions":3327},[57],[1960,1961],[2465,2466,2467,2468,2451],{"trials":3329,"activeCount":68},[],{"trials":3331,"activeCount":68},[],{"trials":3333,"activeCount":68},[],{"trials":3335,"activeCount":68},[],{"intervention":2466,"totalTrials":64,"cells":3337},{"EARLY_PHASE1":3338,"PHASE1":3340,"PHASE2":3346,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3339,"activeCount":68},[],{"trials":3341,"activeCount":68},[3342],{"nctId":2458,"briefTitle":2459,"status":212,"phases":3343,"completion":2461,"start":2462,"enrollment":8,"conditions":3344,"interventions":3345},[57],[1960,1961],[2465,2466,2467,2468,2451],{"trials":3347,"activeCount":68},[],{"trials":3349,"activeCount":68},[],{"trials":3351,"activeCount":68},[],{"trials":3353,"activeCount":68},[],{"intervention":2467,"totalTrials":64,"cells":3355},{"EARLY_PHASE1":3356,"PHASE1":3358,"PHASE2":3364,"PHASE3":3366,"PHASE4":3368,"NA":3370},{"trials":3357,"activeCount":68},[],{"trials":3359,"activeCount":68},[3360],{"nctId":2458,"briefTitle":2459,"status":212,"phases":3361,"completion":2461,"start":2462,"enrollment":8,"conditions":3362,"interventions":3363},[57],[1960,1961],[2465,2466,2467,2468,2451],{"trials":3365,"activeCount":68},[],{"trials":3367,"activeCount":68},[],{"trials":3369,"activeCount":68},[],{"trials":3371,"activeCount":68},[],{"intervention":2468,"totalTrials":64,"cells":3373},{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3382,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3375,"activeCount":68},[],{"trials":3377,"activeCount":68},[3378],{"nctId":2458,"briefTitle":2459,"status":212,"phases":3379,"completion":2461,"start":2462,"enrollment":8,"conditions":3380,"interventions":3381},[57],[1960,1961],[2465,2466,2467,2468,2451],{"trials":3383,"activeCount":68},[],{"trials":3385,"activeCount":68},[],{"trials":3387,"activeCount":68},[],{"trials":3389,"activeCount":68},[],{"intervention":3391,"totalTrials":64,"cells":3392},"Allogenic placenta derived mesenchymal stem cells",{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3409,"PHASE3":3411,"PHASE4":3413,"NA":3415},{"trials":3394,"activeCount":68},[],{"trials":3396,"activeCount":68},[3397],{"nctId":3398,"briefTitle":3399,"status":212,"phases":3400,"primaryCompletion":3401,"completion":3402,"start":3403,"enrollment":21,"conditions":3404,"interventions":3408},"NCT06360861","Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis",[57],"2024-03-04","2024-03-06","2019-07-23",[3405,3406,3407],"Multiple Sclerosis","Secondary-Progressive Multiple Sclerosis","Mesenchymal Stem Cells",[3391],{"trials":3410,"activeCount":68},[],{"trials":3412,"activeCount":68},[],{"trials":3414,"activeCount":68},[],{"trials":3416,"activeCount":68},[],{"intervention":3418,"totalTrials":64,"cells":3419},"Ketorolac",{"EARLY_PHASE1":3420,"PHASE1":3432,"PHASE2":3434,"PHASE3":3436,"PHASE4":3438,"NA":3440},{"trials":3421,"activeCount":68},[3422],{"nctId":3423,"briefTitle":3424,"status":212,"phases":3425,"primaryCompletion":3426,"completion":3427,"start":3428,"enrollment":3429,"conditions":3430,"interventions":3431},"NCT03665753","Comparison of IV 10, 20, and 30mg for Renal Colic Pain in the ED",[56],"2019-09-09","2019-11-09","2018-11-05",165,[18,228],[3418],{"trials":3433,"activeCount":68},[],{"trials":3435,"activeCount":68},[],{"trials":3437,"activeCount":68},[],{"trials":3439,"activeCount":68},[],{"trials":3441,"activeCount":68},[],{"intervention":3443,"totalTrials":64,"cells":3444},"Liposomal meglumine antimoniate",{"EARLY_PHASE1":3445,"PHASE1":3454,"PHASE2":3456,"PHASE3":3458,"PHASE4":3460,"NA":3462},{"trials":3446,"activeCount":68},[3447],{"nctId":3448,"briefTitle":3449,"status":212,"phases":3450,"primaryCompletion":856,"completion":1662,"start":214,"enrollment":945,"conditions":3451,"interventions":3452},"NCT01050777","Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis",[56],[32],[3443,3443,3453],"Liposomal Paromomycin",{"trials":3455,"activeCount":68},[],{"trials":3457,"activeCount":68},[],{"trials":3459,"activeCount":68},[],{"trials":3461,"activeCount":68},[],{"trials":3463,"activeCount":68},[],{"intervention":3453,"totalTrials":64,"cells":3465},{"EARLY_PHASE1":3466,"PHASE1":3472,"PHASE2":3474,"PHASE3":3476,"PHASE4":3478,"NA":3480},{"trials":3467,"activeCount":68},[3468],{"nctId":3448,"briefTitle":3449,"status":212,"phases":3469,"primaryCompletion":856,"completion":1662,"start":214,"enrollment":945,"conditions":3470,"interventions":3471},[56],[32],[3443,3443,3453],{"trials":3473,"activeCount":68},[],{"trials":3475,"activeCount":68},[],{"trials":3477,"activeCount":68},[],{"trials":3479,"activeCount":68},[],{"trials":3481,"activeCount":68},[],{"intervention":341,"totalTrials":21,"cells":3483},{"EARLY_PHASE1":3484,"PHASE1":3486,"PHASE2":3488,"PHASE3":3490,"PHASE4":3492,"NA":3498},{"trials":3485,"activeCount":68},[],{"trials":3487,"activeCount":68},[],{"trials":3489,"activeCount":68},[],{"trials":3491,"activeCount":68},[],{"trials":3493,"activeCount":68},[3494],{"nctId":332,"briefTitle":333,"status":212,"phases":3495,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":3496,"interventions":3497},[60],[23],[341,342,295],{"trials":3499,"activeCount":68},[3500,3506,3514,3521],{"nctId":3501,"briefTitle":3502,"status":212,"phases":3503,"primaryCompletion":214,"completion":374,"start":551,"enrollment":1894,"conditions":3504,"interventions":3505},"NCT01521624","Metformin Effects on Oxidative Stress Parameters in Newly Diagnosed Type 2 Diabetes Patients",[61],[15],[341],{"nctId":3507,"briefTitle":3508,"status":212,"phases":3509,"primaryCompletion":1166,"completion":856,"start":636,"enrollment":3510,"conditions":3511,"interventions":3512},"NCT01593371","Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients",[61],98,[15],[341,3513],"Pioglitazone",{"nctId":3515,"briefTitle":3516,"status":212,"phases":3517,"primaryCompletion":375,"completion":3518,"start":259,"enrollment":526,"conditions":3519,"interventions":3520},"NCT01963663","Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients",[61],"2013-04",[15],[341,3513],{"nctId":3522,"briefTitle":3523,"status":212,"phases":3524,"primaryCompletion":1662,"completion":225,"start":856,"enrollment":3525,"conditions":3526,"interventions":3527},"NCT02027103","Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients",[61],102,[15],[341,3513],{"intervention":3513,"totalTrials":33,"cells":3529},{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3534,"PHASE3":3536,"PHASE4":3538,"NA":3540},{"trials":3531,"activeCount":68},[],{"trials":3533,"activeCount":68},[],{"trials":3535,"activeCount":68},[],{"trials":3537,"activeCount":68},[],{"trials":3539,"activeCount":68},[],{"trials":3541,"activeCount":68},[3542,3546,3550],{"nctId":3507,"briefTitle":3508,"status":212,"phases":3543,"primaryCompletion":1166,"completion":856,"start":636,"enrollment":3510,"conditions":3544,"interventions":3545},[61],[15],[341,3513],{"nctId":3515,"briefTitle":3516,"status":212,"phases":3547,"primaryCompletion":375,"completion":3518,"start":259,"enrollment":526,"conditions":3548,"interventions":3549},[61],[15],[341,3513],{"nctId":3522,"briefTitle":3523,"status":212,"phases":3551,"primaryCompletion":1662,"completion":225,"start":856,"enrollment":3525,"conditions":3552,"interventions":3553},[61],[15],[341,3513],{"intervention":3555,"totalTrials":347,"cells":3556},"Melatonin",{"EARLY_PHASE1":3557,"PHASE1":3559,"PHASE2":3561,"PHASE3":3573,"PHASE4":3575,"NA":3577},{"trials":3558,"activeCount":68},[],{"trials":3560,"activeCount":68},[],{"trials":3562,"activeCount":68},[3563],{"nctId":3564,"briefTitle":3565,"status":212,"phases":3566,"primaryCompletion":3567,"completion":3568,"start":551,"enrollment":3569,"conditions":3570,"interventions":3572},"NCT01279876","Melatonin in Relapsing-Remitting Multiple Sclerosis Patients",[58],"2014-01","2014-02",25,[3571],"Multiple Sclerosis, Relapsing-Remitting",[3555],{"trials":3574,"activeCount":68},[],{"trials":3576,"activeCount":68},[],{"trials":3578,"activeCount":68},[3579],{"nctId":3580,"briefTitle":3581,"status":212,"phases":3582,"primaryCompletion":487,"completion":324,"start":896,"enrollment":678,"conditions":3583,"interventions":3585},"NCT02463318","The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects",[61],[3405,3584],"Oxidative Stress",[3555],{"intervention":3587,"totalTrials":347,"cells":3588},"Acetazolamide",{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3593,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3590,"activeCount":68},[],{"trials":3592,"activeCount":68},[],{"trials":3594,"activeCount":68},[3595],{"nctId":3596,"briefTitle":3597,"status":256,"phases":3598,"primaryCompletion":467,"completion":324,"start":3025,"enrollment":1577,"conditions":3599,"interventions":3606},"NCT01867268","Effect of Acetazolamide & Position in CSF Leakage and Collection and Wound Dehiscence",[58],[3600,3601,3602,3603,3604,3605],"Fibrolipoma of Filum Terminale","Lipomyelomeningocele","Split Cord Malformation","Dermal Sinus","Tethered Cord Syndrome","Tumor",[3587],{"trials":3608,"activeCount":68},[],{"trials":3610,"activeCount":68},[],{"trials":3612,"activeCount":68},[3613],{"nctId":3614,"briefTitle":3615,"status":256,"phases":3616,"primaryCompletion":3617,"completion":3618,"start":3619,"enrollment":184,"conditions":3620,"interventions":3622},"NCT03847571","Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome",[],"2019-10-30","2019-12-30","2019-01-10",[3621],"Bartter Syndrome",[3587],{"intervention":1775,"totalTrials":347,"cells":3624},{"EARLY_PHASE1":3625,"PHASE1":3627,"PHASE2":3629,"PHASE3":3631,"PHASE4":3637,"NA":3639},{"trials":3626,"activeCount":68},[],{"trials":3628,"activeCount":68},[],{"trials":3630,"activeCount":68},[],{"trials":3632,"activeCount":68},[3633],{"nctId":1767,"briefTitle":1768,"status":212,"phases":3634,"primaryCompletion":1770,"completion":524,"start":1771,"enrollment":1772,"conditions":3635,"interventions":3636},[59],[18],[1775,1756],{"trials":3638,"activeCount":68},[],{"trials":3640,"activeCount":68},[3641],{"nctId":3642,"briefTitle":3643,"status":212,"phases":3644,"primaryCompletion":969,"completion":969,"start":286,"enrollment":216,"conditions":3645,"interventions":3647},"NCT01860248","Vapocoolant Spray Effectiveness On Arterial Puncture Pain: Randomized Double Blind Placebo-Controlled Trial",[61],[3646],"Puncture Site Pain",[1775,3648],"Water spray",{"intervention":3650,"totalTrials":64,"cells":3651},"four doses of Euvax B vaccine",{"EARLY_PHASE1":3652,"PHASE1":3654,"PHASE2":3656,"PHASE3":3658,"PHASE4":3660,"NA":3662},{"trials":3653,"activeCount":68},[],{"trials":3655,"activeCount":68},[],{"trials":3657,"activeCount":68},[],{"trials":3659,"activeCount":68},[],{"trials":3661,"activeCount":68},[],{"trials":3663,"activeCount":68},[3664],{"nctId":3665,"briefTitle":3666,"status":212,"phases":3667,"primaryCompletion":3668,"completion":3668,"start":3668,"enrollment":3669,"conditions":3670,"interventions":3672},"NCT01468051","Two Schedules of Hepatitis B Vaccination in Predialysis Chronic Renal Failure Patients",[61],"2008-10",51,[3671],"Renal Failure",[3650,3673],"20 μg (1 ml) three doses of Euvax B vaccine",{"intervention":3673,"totalTrials":64,"cells":3675},{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3677,"activeCount":68},[],{"trials":3679,"activeCount":68},[],{"trials":3681,"activeCount":68},[],{"trials":3683,"activeCount":68},[],{"trials":3685,"activeCount":68},[],{"trials":3687,"activeCount":68},[3688],{"nctId":3665,"briefTitle":3666,"status":212,"phases":3689,"primaryCompletion":3668,"completion":3668,"start":3668,"enrollment":3669,"conditions":3690,"interventions":3691},[61],[3671],[3650,3673],{"intervention":3693,"totalTrials":64,"cells":3694},"Valacyclovir",{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3699,"PHASE3":3701,"PHASE4":3703,"NA":3705},{"trials":3696,"activeCount":68},[],{"trials":3698,"activeCount":68},[],{"trials":3700,"activeCount":68},[],{"trials":3702,"activeCount":68},[],{"trials":3704,"activeCount":68},[],{"trials":3706,"activeCount":68},[3707],{"nctId":3708,"briefTitle":3709,"status":212,"phases":3710,"primaryCompletion":3711,"completion":3712,"start":3713,"enrollment":3714,"conditions":3715,"interventions":3717},"NCT07014397","Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth",[61],"2025-03-22","2025-03-26","2024-11-01",38,[3716],"Symptomatic Apical Periodontitis",[3693],{"intervention":3719,"totalTrials":64,"cells":3720},"Indomethacin",{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3725,"PHASE3":3727,"PHASE4":3729,"NA":3731},{"trials":3722,"activeCount":68},[],{"trials":3724,"activeCount":68},[],{"trials":3726,"activeCount":68},[],{"trials":3728,"activeCount":68},[],{"trials":3730,"activeCount":68},[],{"trials":3732,"activeCount":68},[3733],{"nctId":3734,"briefTitle":3735,"status":256,"phases":3736,"primaryCompletion":3737,"start":2659,"enrollment":3738,"conditions":3739,"interventions":3741},"NCT02368795","Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis",[61],"2017-01",400,[3740],"Pancreatitis",[3719,3742,3743],"Isosorbide Dinitrate","Ringer's lactate",{"intervention":3742,"totalTrials":64,"cells":3745},{"EARLY_PHASE1":3746,"PHASE1":3748,"PHASE2":3750,"PHASE3":3752,"PHASE4":3754,"NA":3756},{"trials":3747,"activeCount":68},[],{"trials":3749,"activeCount":68},[],{"trials":3751,"activeCount":68},[],{"trials":3753,"activeCount":68},[],{"trials":3755,"activeCount":68},[],{"trials":3757,"activeCount":68},[3758],{"nctId":3734,"briefTitle":3735,"status":256,"phases":3759,"primaryCompletion":3737,"start":2659,"enrollment":3738,"conditions":3760,"interventions":3761},[61],[3740],[3719,3742,3743],{"intervention":3743,"totalTrials":64,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3768,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3765,"activeCount":68},[],{"trials":3767,"activeCount":68},[],{"trials":3769,"activeCount":68},[],{"trials":3771,"activeCount":68},[],{"trials":3773,"activeCount":68},[],{"trials":3775,"activeCount":68},[3776],{"nctId":3734,"briefTitle":3735,"status":256,"phases":3777,"primaryCompletion":3737,"start":2659,"enrollment":3738,"conditions":3778,"interventions":3779},[61],[3740],[3719,3742,3743],{"intervention":3781,"totalTrials":64,"cells":3782},"low molecular weight heparin",{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3789,"PHASE4":3791,"NA":3793},{"trials":3784,"activeCount":68},[],{"trials":3786,"activeCount":68},[],{"trials":3788,"activeCount":68},[],{"trials":3790,"activeCount":68},[],{"trials":3792,"activeCount":68},[],{"trials":3794,"activeCount":68},[3795],{"nctId":3796,"briefTitle":3797,"status":212,"phases":3798,"primaryCompletion":214,"completion":214,"start":214,"enrollment":3799,"conditions":3800,"interventions":3802},"NCT01356615","Low Molecular Weight Heparin for Hemodialysis Anticoagulation",[61],27,[3801],"End Stage Renal Failure on Dialysis",[3781,3803],"standard unfractionated heparin",{"intervention":3803,"totalTrials":64,"cells":3805},{"EARLY_PHASE1":3806,"PHASE1":3808,"PHASE2":3810,"PHASE3":3812,"PHASE4":3814,"NA":3816},{"trials":3807,"activeCount":68},[],{"trials":3809,"activeCount":68},[],{"trials":3811,"activeCount":68},[],{"trials":3813,"activeCount":68},[],{"trials":3815,"activeCount":68},[],{"trials":3817,"activeCount":68},[3818],{"nctId":3796,"briefTitle":3797,"status":212,"phases":3819,"primaryCompletion":214,"completion":214,"start":214,"enrollment":3799,"conditions":3820,"interventions":3821},[61],[3801],[3781,3803],{"intervention":3823,"totalTrials":64,"cells":3824},"Etanercept, Methotrexate, Prednisolone",{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3829,"PHASE3":3831,"PHASE4":3833,"NA":3835},{"trials":3826,"activeCount":68},[],{"trials":3828,"activeCount":68},[],{"trials":3830,"activeCount":68},[],{"trials":3832,"activeCount":68},[],{"trials":3834,"activeCount":68},[],{"trials":3836,"activeCount":68},[3837],{"nctId":3838,"briefTitle":3839,"status":256,"phases":3840,"primaryCompletion":3025,"completion":3841,"start":551,"enrollment":216,"conditions":3842,"interventions":3845},"NCT00931957","Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease",[61],"2013-10",[3843,3844],"Behcet Syndrome","Uveal Disease",[3823],{"intervention":3847,"totalTrials":64,"cells":3848},"gentamicin",{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3853,"PHASE3":3855,"PHASE4":3857,"NA":3859},{"trials":3850,"activeCount":68},[],{"trials":3852,"activeCount":68},[],{"trials":3854,"activeCount":68},[],{"trials":3856,"activeCount":68},[],{"trials":3858,"activeCount":68},[],{"trials":3860,"activeCount":68},[3861],{"nctId":3862,"briefTitle":3863,"status":212,"phases":3864,"primaryCompletion":336,"completion":336,"start":1893,"enrollment":3865,"conditions":3866,"interventions":3868},"NCT01148693","Gentamicin in Preventing Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Cholangitis in Non-calculus Stenting",[61],114,[3867],"Cholangitis",[3847],{"intervention":3648,"totalTrials":64,"cells":3870},{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3875,"PHASE3":3877,"PHASE4":3879,"NA":3881},{"trials":3872,"activeCount":68},[],{"trials":3874,"activeCount":68},[],{"trials":3876,"activeCount":68},[],{"trials":3878,"activeCount":68},[],{"trials":3880,"activeCount":68},[],{"trials":3882,"activeCount":68},[3883],{"nctId":3642,"briefTitle":3643,"status":212,"phases":3884,"primaryCompletion":969,"completion":969,"start":286,"enrollment":216,"conditions":3885,"interventions":3886},[61],[3646],[1775,3648]]